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1.
1.1
1.11

INTRODUCTION

Effects of opiates on whole animals

The pharmacology of opiates:

analgesia

For centuries, mankind has known of the medicinal value and
psychological effects of opium, which is a powder obtained from the
seed of the poppy plant, Papaver somniferum.

The major ingredient of

opium which is responsible for its pharmacological effects is the alkaloid morphine.
Morphine and other opiates produce analgesia (Jaffe & Martin,
1975); this action is the basis for the extensive clinical use of these
drugs.

The analgesia produced by morphine is selective in that it

occurs without loss of consciousness and without obtunding other sensory input.

There are two aspects to pain:

pain as a discriminative

sensation, and pain as a subjective experience.

The subjective experi-

ence of pain encompasses the emotional reactions to the painful
sensation, which include anxiety, fear and "suffering."

Opiates are

especially effective in relieving this subjective aspect of pain.
Other pharmacological effects of opiates include respiratory depression, meiosis, decreased intestinal motility and psychological actions
such as drowsiness and mental clouding (Jaffe & Martin, 1975).
Animal models are used to assess morphine-induced analgesia.

The

subjective aspect of pain as "suffering," which is the component of
pain most amenable to relief by morphine, cannot be measured in animals
1

2

therefore the effect of morphine is tested on the responses of animals
to stimuli that are considered noxious, such as radiant heat, irritating chemicals or pinching of the skin.

One such method in common

use is the tail-flick test in rodents (D'Amour & Smith, 1941).

In this

procedure the tail of a restrained rat or mouse is placed in a groove,
and a high intensity lamp is positioned above the groove.

The experi-

menter measures the time interval between switching on the lamp and the
response of the animal to the heat generated by the lamp.
response is

~

characteristic twitch of the tail.

This

Opiates increase the

duration of time before the animal flicks its tail.

Although this test

is useful for evaluating the antinociceptive activity of drugs,
D'Amour & Smith (1941) make no claims that the results can be extrapolated to predict the analgesic activity of drugs against deep-seated,
continuous pain such as that involved in carcinoma.
Other procedures for evaluating the antinociceptive activity of
opiates include placing a rodent on a hot plate and measuring the time
before it licks its paws or jumps (hot-plate test), and tests which
involve placing a clamp on the tail of a rodent and evaluating either
vocal responses or attempts to bite the clamp.
1.12

The opiate receptor
Opiates produce analgesia by binding to receptors on neurons and

thus altering the activity of those neurons.

A receptor is a macromo-

lecular entity on the membrane of a cell that binds a given class of
structurally similar molecules with high affinity and selectivity; the

3

interaction between the molecule and the receptor produces a characteristic response (Goldstein, Aranow & Kalman, 1974).

Saturable, high

affinity binding sites for opiates have been identified in isolated
neuronal tissue (Pert & Snyder, 1973a; Simon, Hiller & Edelman, 1973;
Terenius, 1973) and have been localized to homogenate fractions containing synaptic membranes (Pert, Snowman & Snyder, 1974).

Although

direct evidence is lacking that these binding sites are equivalent to
the opiate receptors, the two share essential features (Hollt & Wuster,
'J

197~).

For example, the affinity of a series of opiate compounds for

~

binding sites parallels their pharmacological potency in a given
tissue (central nervous system:
nervous system:

Pert & Snyder, 1973b; peripheral

Creese & Snyder, 1975).

Also, opiates bind to these

sites with much higher affinity than do compounds without opiate activity.

Lastly, both binding and receptor activity are stereospecific;

levo-isomers of opiates are more effective than dextro-isomers of the
enantiomeric pair.
Opiate binding sites are unevenly distributed in the brain
(Hiller, Pearson & Simon, 1973; Kuhar, Pert & Snyder, 1973).

Some

areas, such as_ structures associated with the limbic system, exhibit q
high amount of binding, whereas others (cerebellum, white matter) have
little or no binding.
1.13

Endogenous opioid peptides
It is intuitively unlikely that high affinity, stereospecific

binding sites should exist in brain in order to interact with alkaloids

4
extracted from the seed of the poppy.

A search for endogenous agonists

for the opiate receptor resulted in the discovery of the enkephalins
(Hughes, Smith, Kosterlitz, Fotherfill, Morgan & Morris, 1975).

The

enkephalins are two structurally related pentapeptides that differ only
in their carboxy-terminal amino acid:

5
Tyr-Gly-Gly-Phe-Met for Met -

5
enkephalin and Tyr-Gly-Gly-Phe-Leu for Leu -enkephalin.

Opiate-like

substances have also been isolated from extracts of pituitary gland.
One of these substances, S-endorphin, is a 31-amino acid peptide with
5
the sequence of Met -enkephalin at its carboxy terminus (Cox, Goldstein

& Li, 1976).
(0.5 - 1.0

S-endorphin, administered by the intracerebral route

~g)

to a mouse, has potent antinociceptive activity as

assessed by the hot-plate and tail-flick methods (Loh, Tseng, Wei & Li,
1976).

5
In contrast, high doses of Met -enkephalin (Ec

5
Leu -enkephalin (EC

50

= 240 ~g)

50

=

75

~g) and

must be administered intracerebro-

ventricularly to produce a short-lasting (2-5 min) antinociception in
mice (Buscher, Hill, Romer, Cardinaux, Closse, Hauser & Pless, 1976).
This result can be explained by the rapid enzymatic degradation of
these peptides.

Structural analogs of the enkephalins which are

resistant to enzymatic degradation have been synthesized.

One such

2
5
analog, D-Ala -Met -enkephalinamide (DAEA), has potent, long-lasting
(up to 2 h) antinociceptive activity (tail-flick test) if injected
(5 or 10

~g)

directly into the periaqueductal region of rat brain

(Pert, Pert, Chang & Fong, 1976).

5
1.2
1.21

Effects of opiates on single neurons

In vivo
Morphine and other opiates alter the firing rate of single

neurons as measured by extracellular recordings from intact animals.
Several criteria are used to ascertain if a given alteration in
neuronal activity induced by application of an opiate drug is mediated
by interaction with opiate receptors.
concentrations of opiate agonists.

The effect should occur with low

The effect should be stereospecific:

mimicked by (-) isomers but less effectively by (+) isomers of opiate
agonists, and blocked by (-) isomers but not (+) isomers of opiate
antagonists.

Also, the effect should be prevented or reversed by low

concentrations of naloxone.

The most common stereospecific, naloxone-

reversible effect of opiates is inhibition of neuronal firing
(Zieglgansberger & Fry, 1978).

Such neuronal activity may be sponta-

neous or induced by iontophoretic application of excitatory substances
such as L-glutamate.

The activity of single neurons in the frontal

regions of the cerebral cortex, the striatum, thalamus, brain stem and
dorsal horn

o~

the spinal cord is inhibited by systemic or ionto-

phoretic application of opiates.

Two exceptions to this generaliza-

tion are pyramidal cells of the hippocampus and Renshaw cells of the
ventral horn of the spinal cord; opiates predominantly excite these
neurons.

The correlation between the sensitivity to opiates of neurons

in a given brain region and the density of opiate binding sites in that
same region is good.

For example, morphine inhibits the firing of

6
neurons in the noradrenergic nucleus locus coeruleus (Korf, Bunney &
Aghajanian, 1974), an area that has a high density of opiate binding
sites (Pert, Kuhar & Snyder, 1976).
North (1979a) discusses the advantages and limitations of extracellular recordings of neuronal activity in vivo.

One advantage is

that neurons are observed in their natural environment with relationships and connections to other cells intact.
anatomically and functionally defined.

Also, the cells can be

The methods of applying drugs

to neurons create difficulties in interpretation of data from extracellular recordings in vivo.

Problems of access and metabolism attend

systemic administration of drugs.

A substance applied systemically

could produce an effect on a given neuron by changing the activity of a
separate population of neurons which project to the recording site, or
could alter neuronal activity by an effect on respiration, blood
pressure or blood flow.

Application of a drug by iontophoresis largely

eliminates these concerns.

But results obtained by iontophoretic

application of drugs should be interpreted with caution because the
transport number for the drug and the location of the pipette relative
to the neuron _under study vary.

The concentration of drug at the

neuronal receptor sites is unknown.

A substance applied by ionto-

phoresis could be producing an effect either by a direct action on the
neuron under study, or by presynaptic modulation of synaptic input to
the neuron.

An example of the latter circumstance is the excitation of

hippocampal pyramidal cells by morphine; this excitation is actually
due to disinhibition in that morphine is depressing the activity of

7

nearby basket cells which tonically inhibit the pyramidal cells
(Zieglgansberger, Siggins, French & Bloom, 1978).
Actions of opiates on neuronal activity in vivo can also be
influenced by the method of preparation of the animal and its physiological condition at the time of the recording.

Thus morphine is more

effective in inhibiting firing of dorsal horn cells in the spinal cord
of animals that are spinalized rather than decerebrate; in decerebrate
animals the cells are already influenced by a strong descending inhibition (see North, 1979a).

Also, the effect of morphine on the activity

of neurons in the dorsal raphe area of the periaqueductal gray region
depends on the presence or absence of general anaesthesia (Urea &
Liebeskind, 1979).

The initial activity level of the neurons as influ-

enced by anaesthesia may determine the presence or direction of an
effect of morphine on firing rates.

There is some evidence that

opiates are more likely to inhibit a neuron that is firing at a high
frequency (North, 1979a).
1.22

In vitro
Tissues

~ontaining

neurons or nerve processes which possess

opiate receptors can be removed from the animal and maintained in a
viable condition for long periods of time.

The use of such prepara-

tions offers several advantages over the use of in vivo preparations.
The ionic and chemical environment of the tissue may be controlled and
drugs can be applied in known concentrations by superfusion.

The site

of action of drugs can be inferred by intracellular recordings from
single cells or by measurement of transmitter release from nerve

8
terminals.

The use of anaesthetic drugs is avoided.

Neurons which are sensitive to opiates can be found in various
parts of the peripheral nervous system.

The myenteric plexus of the

guinea-pig ileum is a well-studied example.

Morphine inhibits the

activity of the ganglion cells of the myenteric plexus (Satoh,
Takayanagi & Takagi, 1973; Dingledine & Goldstein, 1976).

The activity

recorded by the extracellular glass suction electrodes arises from
mechanical irritation of the cells by these electrodes (North &
Williams, 1977).

Enkephalins and S-endorphin also inhibit the firing

of these cells (North & Williams, 1976; Williams & North, 1979).
Neurons grown in tissue culture have also been used to study the
actions of opiates.

5
Several effects of Leu -enkephalin applied by

iontophoresis to cultured mouse spinal neurons have been observed
during intracellular recordings from these cells (Barker, Gruol, Huang,
Neale & Smith, 1978; Barker, Smith & Neale, 1978).

Rapid depolariza-

tions (in 10% of cells) and slow hyperpolarizations (in 33% of cells)
have been observed upon application of enkephalin to cell somata.

Both

responses are associated with a change in membrane input resistance.
In other cells_ (12/37 tested), enkephalin directly depresses excitability by elevating the threshold for generation of action potentials
by intracellular injection of depolarizing current, an action that is
sometimes antagonized by naloxone (3/6 cells tested).

The depression

of excitability is not associated with changes in resting membrane
properties in the majority of cells (8/12).

A third action of

enkephalin in these cells is modulation of responses to iontophoretic

9
application of amino acids.

For example, glutamate-induced depolariza-

tions are either inhibited (28/32 cells) or not affected (4/32 cells)
5
by Leu -enkephalin.

The depression of the glutamate response is not

accompanied by changes in resting membrane properties, and can be partially prevented by co-iontophoresis of naloxone together with
enkephalin (6/10 cells).
Caution should be exercised in evaluating the relevance of these
studies to physiological actions of opiates in vivo.
grow in

mono~ayers,

Cultured neurons

whereas brain structure is three-dimensional.

Definite alterations from the usual neuronal organization and physiology thus occur.

However, such cells are useful for studying drug

actions on neuronal membrane properties and on monosynaptic transmission.
Maintenance of slices of brain tissue in vitro is a difficult
technique that offers promise for elucidating the mechanisms of action
of opiates on central neurons without the problems associated with in
situ recording (see above).

Intracellular recordings have been made

from neurons located in the nucleus locus coeruleus of slices of
guinea-pig pons (Pepper & Henderson, 1979).

When these cells are

superfused with solutions containing normorphine (300 nM- 3

~M),

hyperpolarizations associated with a decrease in input membrane resistance are observed (Henderson, personal communication).

These hyper-

polarizations may underlie the decrease in activity of these neurons
when morphine is iontophoretically applied to them in situ (Korf
~

al., 1974).

10
1.23

Effects of prolonged exposure
Repeated

admin~stration

of narcotics leads to the development of

tolerance to their acute effects.

Tolerance is a "state in which

repetition of the same dose of a drug has progressively less effect, or
in which the dose needs to be increased to obtain the same degree of
pharmacological effect as was caused by the original dose" (Isbell &
Chrusciel, 1970).
dence.

Repeated exposure to narcotics also produces depen-

Dependence is a state, "resulting from the interaction between

a living organism and a drug" (Isbell & Chrusciel, 1970), characterized
by the appearance of an abstinence or withdrawal syndrome when morphine
administration is discontinued or when the action of morphine is terminated by a narcotic antagonist such as naloxone (Jaffe, 1975).
1.231 In vivo
Neurons can be exposed to morphine in vivo for long periods of
time by treatment of an animal with repeated systemic injections of
morphine, a single injection of a sustained release formulation of the
drug

~r

by implantation of morphine-containing pellets.

After animals

are chronically treated with morphine, the drug becomes less effective
in depressing spontaneous or evoked firing of single neurons in
several brain regions (Satoh, Zieglgansberger & Herz, 1976; Aghajanian,
1978; Dafny, Brown, Burks & Rigor, 1979).

These results may indicate

that tolerance to the inhibitory action of morphine has developed.
Another interpretation is that only the activity of morphine-insensitive neurons is recorded because the activity of morphine-sensitive
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cells is suppressed by the continuous presence of the drug in vivo.

Or

the observed tolerance may be a secondary consequence of systemic
changes in the levels of circulating hormones (Gibson & Pollock, 1975).
A greater percentage of neurons respond to the iontophoretic
application of naloxone with an increase in their firing rate in
morphine-pretreated animals as compared to naive animals (Frederickson,
Norris & Hewes, 1975; Fry, Zieglgansberger & Herz, 1978).

Extra-

cellular recording from single neurons in vivo cannot distinguish
between at least two mechanisms for this excitatory action of naloxone.
The neurons could increase their firing rate in response to naloxone as
a result of altered synaptic input such as the enhanced release of an
excitatory transmitter or the decreased release of an inhibitory transmitter from nerve terminals.

Or the morphine-sensitive neurons them-

selves could become more excitable.

In either case, the effect of

naloxone could be simply a reversal of the depression of neuronal
activity caused by the continuous presence of morphine, and not a
manifestation of precipitated withdrawal.

One could argue against this

possibility by demonstrating that the neurons in morphine-pretreated
animals fire spontaneously at the same frequency as they do in naive
animals (Aghajanian, 1978).
1.232 In vitro
The cellular adaptation which results in tolerance takes place if
neurons are continuously exposed to opiates in vitro as well as in vivo,
as has been demonstrated with the opiate-sensitive neurons of the
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myenteric plexus of the guinea-pig ileum.

If tissues are incubated for

24 h in Krebs solution containing morphine (1

~M),

then the firing rate

of single neurons usually is not changed by higher concentrations of
morphine (10 or 30

~M)

(North & Karras, 1978b).

The activity of these

neurons is usually depressed by much lower concentrations of opiates
(10 nM- 1

~M

normorphine:

North & Williams, 1977).

The tolerance to

morphine occurs in these cells even if the tissues are incubated in
vitro for 24 h with hyoscine and hexamethonium together with morphine;
these drugs

~nhibit

synaptic activity in the myenteric plexus.

Thus

transsynaptic activity is not required for the development of tolerance
to opiates at the level of the single neuron.
The addition of naloxone to myenteric neurons which have been
chronically exposed to morphine in vitro results in a marked increase
in their firing rate (North & Karras, 1978b).

The firing frequencies

seen under these circumstances are never observed in naive tissues.
Thus naloxone produces a withdrawal syndrome in these neurons; this
phenomenon may be characterized by an enhanced excitability of the
cells.
1.24

Cellular sites of action
The action of opiate drugs on single neurons has thus been exam-

ined in both in vivo and in vitro preparations.

This work has revealed

that opiates alter neuronal activity by three mechanisms (see North,
1979b).

First, opiates can have a direct postsynaptic effect on a

neuron, modifying its membrane properties so as to change its excita-
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bility.

A second action, also postsynaptic, is neuromodulation, or

modification of the response of the neuron to transmitters.

This

latter effect occurs without changes in resting membrane properties;
inhibition of transmitter-induced activation or inactivation of ionic
currents could be involved.

A third mechanism of action of opiates is

presynaptic inhibition, or alteration of evoked transmitter release
from axon terminals.
A presynaptic location of opiate binding sites in some brain
regions is suggested by results from binding studies and
graphy.

autoradio~

3
For example, a significant reduction in the binding of [ H]-

naloxone in the upper dorsal horn of the spinal cord is the result of
cutting the dorsal roots (Lamotte, Pert & Snyder, 1976).

This suggests

that the binding sites are associated with the primary afferent terminals.

The results of deafferentation of the vagus and accessory optic

3
systems in the rat also point to a localization of [ H]-diprenorphine
binding sites to the small diameter unmyelinated sensory fibers of
these tracts (Atweh, Murrin & Kuhar, 1978).

However, the possibility

that these binding sites are postsynaptic in location and are reduced
in number by deafferentation because of transsynaptic degeneration
cannot be dismissed.

Definitive localization of opiate binding sites

to either nerve terminals or nerve cell bodies in brain awaits refinements in anatomical techniques such that autoradiography can be applied
to electron micrographs of nerve tissue.
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1.3

Effects of opiates on transmitter release

Opiates inhibit transmitter release from neurons in several parts
of the peripheral autonomic nervous system.

Two methods are used to

estimate transmitter release from autonomic nerve terminals (see
Starke, 1977).

One method is to measure the mechanical response of the

postsynaptic effector cell, the smooth muscle.

The general procedure

is to suspend the tissue in an organ bath through which heated Krebs
solution is superfused.

One end of the tissue is fixed to a rod or

loop at the bottom of the bath, and the other end is attached to a
force or a linear-motion transducer.

Field stimulation of the intra-

mural nerves is applied by two wire or ring electrodes situated at the
top and bottom of the bath.

The transmitter released from the nerve

terminals in response to electrical stimuli produces either a change in
length or a change in tension of the organ.

Any change in this mecha-

nical response that occurs upon addition of a drug to the bathing
medium may reflect a modification of transmitter release, but it may
also result from postsynaptic effects of the drug.

Such effects include

changes in sensitivity to transmitter, or changes in the efficiency of
the excitation-contraction coupling process of the muscle.

Post-

synaptic effects of a drug are less likely if the drug in question does
not change the response of the organ to direct application of transmitter substance.
Another method of measuring nerve-evoked transmitter release is
to measure the amount of transmitter overflowing into the superfusing
Krebs solution in response to stimulation of nerves either with elec-
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trical stimulus pulses or with depolarizing solutions of high potassium
ion concentration.

The overflow evoked by such stimuli is distin-

guished from the "spontaneous" overflow.

Overflow represents the

difference between the amount of transmitter released from nerves and
the amount of transmitter taken back up into cells after its release
(such reuptake may be neuronal or extraneuronal) .

Overflow of trans-

mitter may be estimated chemically or by bioassay.

Another technique

for estimating overflow is to preload the tissue with radiolabelled
transmitter and to count the radioactivity released into the superfusion fluid.

It is important to exclude an action of a drug on

transmitter reuptake before concluding that the drug alters transmitter
release as estimated by the overflow method.
1.31

Guinea-pig ileum
Morphine inhibits the contractile response of the longitudinal

muscle and also the release of acetylcholine evoked by coaxial stimulation of the guinea-pig ileum with electrical pulses of supramaximal
strength (Paton, 1957).

The action of morphine is localized to neurons

of the myenteric plexus (see above) because acetylcholine release from
tissues which contain only longitudinal muscle and the myenteric plexus
is also sensitive to morphine (Paton & Aboo Zar, 1968).
These actions of opiates on myenteric plexus-longitudinal muscle
strips of guinea-pig ileum are stereospecific and prevented or reversed
by naloxone (see Kosterlitz & Waterfield, 1975).

Enkephalins also

inhibit cholinergic neurotransmission in the guinea-pig ileum (Hughes

16
~

al., 1975b; Waterfield, Smokcum, Hughes, Kosterlitz & Henderson,

1977).
1.32

Mouse vas deferens
A mouse isolated vas deferens which has been stripped of its

connective tissue sheath consists mainly of smooth muscle cells and the
axons and nerve terminals which innervate them.

The noradrenaline

which is released from these nerve terminals in response to electrical
field stimulation is most likely the transmitter which produces the
contractile response of the muscle (see below).

Muscle contractions

elicited by supramaximal electrical stimulation at a frequency of 0.1
Hz are inhibited by morphine (70 nM- 2.3
Kosterlitz, 1972).

~M)

(Henderson, Hughes &

The inhibitory effect of morphine and other opiates

on neurotransmission in this tissue occurs with low concentrations of
drug, is stereospecific (the (-) isomers but not the (+) isomers of
opiate agonists are active), and can be prevented or reversed by
naloxone (Hughes, Kosterlitz & Leslie, 1975).

Fulfillment of these

criteria indicate that this action in the mouse vas deferens is
mediated by specific opiate receptors similar to those found in brain
tissue.

The relative agonist potencies of a series of opiates in

causing an inhibition of neuro-effector transmission in the mouse vas
deferens correlate with the potencies of these same compounds in producing analgesia in man (Hughes et al., 1975a).

The electrically-

5
evoked contractions of the muscle are also inhibited by Met -enkephalin,
5
Leu -enkephalin and S-endorphin (Hughes et al., 1975b; Waterfield
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et al.,
-

1977).

The inhibitory potencies of normorphine (Hughes et al.,

--

5

5
1975a) and Met -enkephalin but not Leu -enkephalin (Hart, Kitchen &
Waddell) are increased by reducing the current strength used to elicit
the muscle contraction.
The spontaneous overflow of labelled catecholamines (after incu3
bation of the vas deferens in solutions containing either [ H]-tyrosine
or [ 3H]-noradrenaline) is not affected by morphine (Hughes et al.,
1975a).

Morphine (Henderson et al., 1972) and enkephalin (Waterfield

et al., 1977) do inhibit the overflow of noradrenaline evoked by electrical stimulation of the intramural nerves.

The concentrations of

opiates which inhibit noradrenaline overflow are similar to the concentrations which inhibit the muscle contractions.

The effect of opiates

on transmitter release is dependent on the frequency of nerve stimulation used to evoke the release:

morphine (1

~M)

depresses the frac-

tiona! noradrenaline output per pulse at a stimulation frequency of 1.5
Hz but not at 15Hz (Henderson & Hughes, 1976).
Opiates and opioid peptides therefore inhibit nerve-evoked muscle
contractions and transmitter release in the mouse vas deferens.

The

response of the smooth muscle to exogenous noradrenaline is, however,
not altered by these substances (Henderson & Hughes, 1976).

These

results indicate that the opiate receptors in this tissue are located
presynaptically on the adrenergic nerves and not postsynaptically on
the smooth muscle cells.
The potency of morphine and opioid peptides in inhibiting neurotransmission in the vas deferens is dependent on the strain of mouse
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used for the experiment.

For example, morphine (1

~M)

inhibits con-

tractions and noradrenaline release from vasa removed from T.O. mice,
but not from vasa of C57/BL mice (Henderson & Hughes, 1976).

On the

5
5
other hand, Met -enkephalin and Leu -enkephalin are approximately equipotent in vasa from both of these strains (Waterfield, Lord, Hughes &
Kosterlitz, 1978).

In a study of seven different strains of mice,

Szerb & Vohra (1979) found no correlation between sensitivity to nor5
morphine and sensitivity to Met -enkephalin.

The contractions of the

isolated vas deferens of the rat are not inhibited by either morphine
or the enkephalins except in very high concentrations.
however, sensitive to S-endorphin, with an Ec

50

This tissue is,

of 130 nM for inhibi-

tion of the muscle contractions (Lemaire, Magnan & Regoli, 1978).

This

effect of S-endorphin on the rat vas deferens is reversed by naloxone.
The differential sensitivities to opiates and opioid peptides of
vasa from different species and from different strains of the same
species suggests a heterogeneity of receptor populations.

The concept

of multiple types of opiate receptor originated with Martin and his
colleagues (Martin, Eades, Thompson, Hupplier & Gilbert, 1976).

Based

on the behavioral and electrophysiological effects of various morphine
derivatives which they observed in the chronic spinal dog preparation,
these investigators postulated the existence of three classes of opiate
receptor.
with the

In their scheme, typical morphine-like compounds interact
~

receptor.

Another system of classification of opiate recep-

tors was proposed by Lord, Waterfield, Hughes & Kosterlitz (1977) based
on the following evidence.

First is the comparison of the pharmacolog-
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ical potencies of opiates and opioid peptides in the guinea-pig ileum
and mouse vas deferens bioassay systems.

The mouse vas deferens is

less sensitive to morphine than is the guinea-pig ileum; the opposite
is true for the potencies of the enkephalins.
effective in these two systems.

S-endorphin is equally

Secondly, measurement of the potency

of opiates and opioid peptides in inhibiting the binding of labelled
ligands to homogenates of guinea-pig brain reveals the presence of two
distinct binding sites.

Some opiates are more potent inhibitors of the

3
binding of [ H]-naloxone whereas others preferentially inhibit the

3
5
binding of [ H]-Leu -enkephalin.

Lord et al. (1977) propose that the

sites which preferentially bind naloxone and morphine are

~

receptors

5
and the sites which preferentially bind Leu -enkephalin are 8 receptors.

In the guinea-pig ileum, enkephalins interact mainly with

the~

receptor, whereas in the mouse vas deferens they probably interact with
the putative 8 receptor.

To account for the selective sensitivity of

the rat vas deferens to S-endorphin, a receptor which preferentially
binds this substance (the

E

receptor) has been postulated (Wuster,

Schulz & Herz, 1979).
The vasa deferentia of mice which are sensitive to enkephalins
but not morphine (C57/BL strain) presumably possess many 8 receptors
but

few~

receptors.

Vasa of mice of the T.O. strain, which are sensi-

tive to normorphine, presumably possess comparatively more functional
receptors.

Apparently the ratio

of~-

~

and a-receptors in the mouse vas

deferens is variable and genetically determined (Waterfield et al.,
1978).

5
3
Recently specific binding sites for [ 3H]-Met -enkephalin, [ H]-
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3
dihydromorphine and [ H]-naltrexone have been demonstrated for the
first time in the vas deferens of the T.O. strain of mouse (Leslie &
Kosterlitz, 1979).

Such binding can only be observed if tissue homo-

genates are incubated with labelled ligand at 0° C, and not at 37° C.
The affinity of naltrexone for opiate binding sites is lower in the
mouse vas deferens than in the guinea-pig ileum.

Because the opiate

antagonists naltrexone and naloxone preferentially bind to the

~

recep-

tor and bind less potently to the 8 receptor, this result is compatible
with the view that the mouse vas deferens has relatively more 8 receptors than the guinea-pig ileum.

More accurate quantitation of

~

and 8

binding sites awaits refinements of experimental technique that will
improve the ratio of specific to non-specific binding of opiates that
can be measured in the mouse vas deferens.
1.33

Other neuro-effector junctions
Opiates and/or opioid peptides inhibit transmitter release at

several other autonomic neuro-effector junctions.

Examples of such

systems include adrenergic neurotransmission in the cat nictitating
membrane (Trenftelenburg, 1957), cholinergic neurotransmission in the
sinoatrial node-right atrium preparation of the rabbit (Kennedy & West,
1967) and non-adrenergic inhibitory transmission in the guinea-pig
taenia coli (Shima & Ishii, 1978).

It is not known why opiates inhibit

neuro-effector transmission in some, but not all, autonomic end-organs
(see Henderson, Hughes & Kosterlitz, 1978), although a selective
distribution of opiate receptors is a likely possibility.
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1.34

Slices of brain
Opiates can modify the evoked release of putative neurotrans-

mitter substances from brain slices.

In slices of rat cerebral cortex

3
preincubated with [ H]-noradrenaline, the spontaneous overflow of
tritium is not altered by morphine.

Morphine (100 nM- 10

~M)

did

decrease the augmentation in the overflow of tritium during electrical
field stimulation at frequencies of 0.3-3 Hz (Mentel, Starke & Weber,
1974).

5
Met -enkephalin (100

ru~-

Borowski, Endo & Starke, 1976).

10

~M)

had the same effect (Taube,

In these experiments, the depressions

of stimulus-evoked overflow by morphine and enkephalin were both
blocked by naloxone.

Opioids reduce the release of dopamine from

striatal slices (Loh, Brase, Sampath-Khanna, Mar, Way & Li, 1976) and
the release of substance P from the trigeminal nucleus (Jessel &
Iversen, 1977),

~hilst

increasing the release of purines from cortical

tissue (Fredholm & Vernet, 1978).

In these latter three studies, over-

flow of labelled putative transmitter was induced by superfusion with
high potassium solutions.
In order to evoke the release of a measurable amount of radiolabelled substance from brain slices or peripheral neuro-effector
junctions, high potassium solutions or a high frequency of electrical
stimulation are usually employed.

In the former instance, such concen-

trations of potassium far exceed any that would be encountered physiologically in the extracellular fluid.

Concerning the latter circum-

stance, morphine is a more effective inhibitor of transmitter release
at low rather than at high frequencies of nerve stimulation (Henderson
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& Hughes, 1976).

Measurements of overflow of labelled substances are

thus not the best experiments for evaluating the actions of opiates on
transmitter release.

Transmitter release evoked by single pulse stimu-

lation of nerves is most sensitive to the inhibitory action of opiates.
1.35

Effects of prolonged exposure
The nerve-mediated contractions of the isolated myenteric plexus-

longitudinal muscle preparation of the guinea-pig ileum are less sensitive to inhibition by morphine if the tissue is prepared from a
morphine-pretreated animal (Goldstein & Schulz, 1973; Ward & Takemori,
1976; Johnson, Westfall, Howard & Fleming, 1978).
ance, as assessed by the ratio of the Ec

50

The degree of toler-

value for morphine in

preparations from morphine-pretreated vs. naive animals, ranges from 3
up to 18-fold.

This variation results from differences in experimental

protocols among investigators, such as the schedule of administration
of morphine and the time elapsed between removing tissue from the
animal and testing the degree of tolerance (North & Karras, 1978a).
Most studies of the induction of tolerance in the guinea-pig ileum
involve placing the tissue in drug-free Krebs solution after its
removal from the animal.

This procedure results in withdrawal of the

tissue from the morphine to which it has been continuously exposed in
vivo.

If strips of myenteric plexus-longitudinal muscle from morphine-

pretreated guinea-pigs are maintained in Krebs solution containing
normorphine and then challenged with naloxone, the muscle exhibits a
contracture (Schulz & Herz, 1976).

This response to naloxone rapidly

disappears if the tissue is·washed in morphine-free Krebs solution.
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The contracture results from an action of naloxone on neurons in the
myenteric plexus and not from a direct action on the smooth muscle because it is blocked by tetrodotoxin and atropine.
Tolerance in the guinea-pig ileum is not accompanied by a change
in the sensitivity of the smooth muscle to acetylcholine (Goldstein &
Schulz, 1973; Johnson et al., 1978).

Therefore tolerance must develop

to the effects of opiates on the cholinergic neurons of the myenteric
plexus.

Opiates have two actions on these cells:

inhibition of their

firing rate and inhibition of the amount of acetylcholine they release
(see above).

The tolerance to opiates observed with the contractions

of the muscle may be a consequence of tolerance to either or both-of
these effects.

The release of acetylcholine depends both on the number

of neurons excited by a given stimulus and on the amount of acetylcholine secreted by the nerve terminals of the activated neurons.
For neurons with opiate receptors on their nerve terminals,

t"~vo

mechanisms can explain the development of tolerance to the action of
morphine.

The nerve terminals themselves may adapt to the continuous

presence of opiates so that, during withdrawal, transmitter release in
response to nerve impulses is greatly enhanced as a result of this
compensation (see Mentel, Starke & Taube, 1975).

On the other hand,

the postsynaptic receptors may become supersensitive, allowing synaptic
transmission to return to its normal level ("tolerance") in the face of
a continued depression of transmission by morphine.

Upon withdrawal of

morphine, transmitter release would return to normal, but the postsynaptic supersensitivity would result in a neuronal abstinence syndrome (see Llorens, Martres, Baudry & Schwartz, 1978).
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1.4

Role of cAMP in the actions of opiates on neurons

Adenosine 3' ,5 1 -cyclic monophosphoric acid (cAMP) is formed
from ATP by the membrane-bound enzyme adenylate cyclase.

Cyclic AMP is

believed to be an intracellular "second messenger" that plays a crucial
role in the recognition and transduction of signals generated by the
binding of hormones and transmitters to the external surfaces of excitable membranes (see Nathanson, 1977).

The active substance cAMP is

hydrolyzed to the inactive 5'-AMP by cAMP-specific phosphodiesterases.
Three pieces of evidence implicate cAMP in the actions of
opiates.

Firstly, mice that have received injections of cAMP are less

sensitive to the antinociceptive effect of morphine (Ho, Loh & Way,
1973).

Secondly, opiates inhibit the prostaglandin-stimulated forma-

tion of cAMP in homogenates of rat brain (Collier & Roy, 1974a).
Finally, opiates inhibit the enzyme adenylate cyclase in neuroblastoma
x glioma hybrid tumor cells (Sharma, Nirenberg & Klee, 1975).

These

results led to the proposal that the effects of opiates, such as analgesia, are mediated by an inhibition of the adenylate cyclase system in
opiate-sensitive neurons (Collier & Roy, 1974b).

The relationship

between cAMP and opiates in both in vivo and in vitro svstems has there-

---

"

fore been extensively studied.
1.41

Effects of adenosine cyclic nucleotides and phosphodiesterase
inhibitors on the actions of opiates
Ho et al. (1973) assessed the effects of cyclic nucleotides on

the antinociceptive activity of morphine by using the tail-flick test
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in mice.
cAMP (28

This group found that the intracerebral administration of
~g/mouse)

1 or 35 h before a test dose of morphine produces a

significant decrease in the effectiveness of morphine in inhibiting the
tail-flick response.

Furthermore, the intravenous administration of

cAMP or its dibutyryl derivative, dbcAMP (10 mg/kg), 6 h before the
morphine injection also lessens the effectiveness of morphine.

The

cyclic nucleotides are effective even if these substances are administered 24 h before the tail-flick experiment.
It is difficult to envision how a small quantity of a rapidly
degraded substance such as

c~~.

administered peripherally, can alter

the action of a drug which acts on centrally located neurons.

Morphine

and cAMP could be acting at two completely different sites, for example
two anatomically distinct populations of neurons, in altering the
response of an animal to noxious stimuli.

It is impossible to detect

if intracerebral or intravenous administration of cAMP is elevating
intracellular levels of cAMP in the neurons involved in the antinociceptive activity of morphine.

The site of action of cAMP could even be

peripheral, affecting either the afferent (stimulus perception) or the
efferent (ability of animal to effect movement) limbs of the nociceptive reflex.

One substance can also alter the action of another by

changing the metabolism or distribution of the latter.
ness of the peripheral administration of

cAl~

The effective-

addresses these

possibilities.
An interaction of cAMP and morphine at the level of the single

neuron has been tested in vivo.

Neurons in lamina V of the spinal cord

(spinalized cats) increase their firing rate in response to noxious
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cutaneous stimuli (heat) applied to their peripheral fields.

The

activity induced in these cells by noxious stimuli and recorded by
extracellular electrodes is reduced by iontophoretic application of
morphine (30-250 nA of current, for 4-35 min) into the substantia
gelatinosa (Duggan, Hall & Headley, 1977).

This effect of morphine is

not changed by the simultaneous iontophoretic application of both monobutyryl cAMP and a phosphodiesterase inhibitor (at currents of 150 nA)
through the same multi-barrelled pipette (Duggan & Griersmith, 1979).
By themselves these compounds do not alter the responses of the neurons
to noxious input if administered into the substantia gelatinosa using
similar injection currents in other experiments.

The administration of

phosphodiesterase inhibitors in this and in other experiments is intended to increase the intracellular concentrations of cAMP by preventing metabolism of this substance.
Can pretreatment with cAMP or phosphodiesterase inhibitors block
the effects of morphine on isolated tissues?

The isolated guinea-pig

ileum myenteric plexus-longitudinal muscle preparation has been used to
address this question.
measured in three ways:

The action of morphine on this tissue can be
inhibition of the nerve-evoked twitch of the

muscle, inhibition of evoked acetylcholine release and inhibition of
the firing of single myenteric neurons.

If the twitch response of the

muscle is studied, phosphodiesterase inhibitors interact with morphine
in various ways.

MOrphine is less potent in producing an inhibition of

the muscle contraction in the presence of the phosphodiesterase
inhibitor theophylline (500

~M)

(Sawynok & Jhamandas, 1976), although

other investigators report no effect on the action of morphine of a
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higher concentration (3 mM) of theophylline (Gintzler & Musacchio,
1975).

Morphine is more effective in the presence of the phospho-

diesterase inhibitors RO 20-1724 (100

~M)

and dipyridamole (10 nM),

which themselves also inhibit the twitch.

But the inhibitions of the

contractile responses by norepinephrine and adenosine are also enhanced
in the presence of these compounds.

SQ 20,006 (100

~M),

on the other

hand, has no effect on the action of these inhibitory compounds, or on
the action of morphine (Gintzler & Musacchio, 1975).
phosphodiesterase inhibitors are active.

Thus not all

In these studies an action of

the phosphodiesterase inhibitor at a postsynaptic site, for example on
the response of the muscle to transmitter or the efficiency of the
contractile mechanism, cannot be ruled out.

This objection is overcome

by studying the evoked release of acetylcholine from the myenteric
plexus.
Sawynok & Jhamandas (1979) measured the release of acetylcholine
(by radioenzymatic assay) from longitudinal muscle-myenteric plexus
strips.

Release was evoked by electrical stimulus pulses (36 V, 0.5

ms) at a frequency of 0.1 Hz, for periods of 10 min.
and 3

~M)

inhibited this release.

Morphine (300 nM

The inhibition of release by

morphine was less in tissues perfused with the methylxanthines theophylline (1 mM), caffeine (3 mM) and 1-methyl-3-isobutylxanthine (IBMX)
(1

w~)

but not in tissues exposed to the non-xanthine phosphodiesterase

inhibitors RO 20-1724 (10

~M)

or SQ 20,009 (300

~M).

The authors

attribute the effect of the methylxanthines to an alteration of calcium
fluxes in the nerve terminal, and not to an elevation of cAMP levels by
these substances, because elevated calcium ion concentrations and a
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calcium ionophore also cause an apparent antagonism of the inhibitory
action of morphine.
noted.

Several problems with this release study should be

Some of the phosphodiesterase inhibitors themselves modify the

release of acetylcholine.

Under control conditions, about 20% of the

measured release is spontaneous (not blocked by tetrodotoxin).

If

these compounds change the ratio of spontaneous to evoked release, they
could alter the apparent inhibitory action of morphine, as opiates only
depress evoked transmitter release.
of morphine (300 nM and 3
methylxanthines.

~M)

Also, two different concentrations

have equal potency in the presence of the

Lastly, the results are analyzed by the use of

multiple t tests instead of by an analysis of variance.

This treatment

would tend to increase the likelihood of the appearance of statistical
significance.
A study has been made of the effect of cyclic nucleotides and a
phosphodiesterase inhibitor on the inhibition by morphine of the firing
rate of single neurons in the myenteric plexus.

In tissues in which

cAMP levels would be expected to be elevated (by the administration of
cAMP or dbcAMP, by exposure to prostaglandin E and during phospho2
diesterase inhibition by IBMX), the action of morphine on these cells
was not changed (Karras & North, 1979).

This study, which provides the

most direct measurement in this preparation of the response of a neuron
to occupation of its opiate receptors by morphine, fails to support the
hypothesis that the acute action of morphine in altering neuronal
firing rates is mediated by a decrease in cAMP levels.

On the other

hand, the possibility that the chronic actions of opiates in causing
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tolerance and dependence could be mediated by a change in the neuronal

cAMP apparatus was suggested by these authors.
1.42

The quasi-morphine withdrawal syndrome
The acute systemic administration of phosphodiesterase inhibitors

such as theophylline or IBMX results in behaviors that closely resemble
those seen in morphine-dependent animals that are undergoing withdrawal,
a "quasi-morphine withdrawal syndrome" (QMWS) (Collier, Francis,
Henderson & Schneider, 1974; Francis, Roy & Collier, 1975).

A subse-

quent injection of naloxone further intensifies these behavioral
effects of the phosphodiesterase inhibitors (Francis et al., 1975;
Francis, Cuthbert, Dineen, Schneider & Collier, 1976).

Furthermore,

the administration of methylxanthine phosphodiesterase inhibitors increases the intensity of the symptoms of true naloxone-precipitated
withdrawal from morphine (Collier & Francis, 1975).

Methylxanthines

have other actions in addition to inhibition of the enzyme that metabolizes cAMP (see Sawynok & Jhamandas, 1976 & 1979).

But the rank order

of potency of five phosphodiesterase inhibitors, both xanthines and
non-xanthines, in producing a QMWS correlates with their potency for
the inhibition of cAMP phosphodiesterase (Francis, Cuthbert, Saeed,
Butt & Collier, 1978).

The correlation is not perfect, however, as

papaverine and SQ 20,006 inhibit cAMP phosphodiesterase but do not
induce QMW (Collier, Butt, Francis, Roy & Schneider, 1976).
The QMWS is suppressed by opiate drugs (Collier et al., 1974;
Collier et al., 1976), and their relative potencies in doing so
correspond to their potencies for eliciting antinociception, for
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binding to sites in brain homogenates and for inhibiting neurallyevoked contractions of the guinea-pig ileum (Francis et al., 1978).
But pentobarbitone and haloperidol, which are central nervous system
(CNS) depressants, also suppress quasi-withdrawal behavior (Francis
et al., 1978).
Collier and his colleagues have pointed out the close similarities between the behavior of animals during true morphine abstinence
and during quasi-morphine "abstinence" induced by administration of
phosphodiesterase inhibitors.

These investigators postulate that the

QMWS can be attributed to inhibition of brain phosphodiesterase and
the consequent increase in cAMP levels in neurons.

Therefore they

conclude that the opiate withdrawal syndrome elicited by the administration of naloxone to morphine-dependent animals is associated with an
increase in levels of cAMP in opiate-sensitive neurons.
Are there alternative explanations for the behavioral similarities between true morphine abstinence and quasi-morphine "abstinence"?
If opiate withdrawal involves enhanced excitability of opiate-sensitive
neurons, as has been suggested by North & Karras (1978a), then any
compound that ?on-specifically increases the excitability of a similar
population of neurons would produce a similar pattern of behaviors.
The cell populations affected by phosphodiesterase inhibitors and
opiates could overlap but need not be exactly the same, as a given
behavior can be elicited by more than one neuronal pathway.

Naloxone

would further intensify the excitability of these neurons by removing
any suppression caused by the presence of endogenous opiates.

And any

CNS depressant, opiate or otherwise, would suppress such a general
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excitatory phenomenon.

Once again a major consideration is the site of

action - do phosphodiesterase inhibitors limit their actions to the
pool of neurons that are responsive to opiates?

This question can best

be answered by observations on single neurons or simple neuronal
systems.
1.43

Effects of opiates on cAMP metabolism
The acute or chronic administration of morphine to an animal has

variable effects on cAMP levels or adenylate cyclase activity measured
in brain tissue that has been subsequently isolated from the animal
(Hamprecht, 1978).

The interpretation of these in vivo studies is

difficult as biochemical measurements in the relevant populations of
morphine-sensitive neurons cannot be made.

The majority of activity

measured is derived from opiate-insensitive neurons or from nonneuronal brain components such as glia or blood vessels.

For example,

chronic morphine treatment will elevate the activity of protein kinase,
an enzyme that is regulated by cAMP, even in oligodendroglia (Oguri,
Lee & Loh, 1976).
The same_ problem may apply in evaluating the observed alterations
in cyclic nucleotide levels in brain homogenates or slices that have
been incubated with opiates.

If Collier's hypothesis of the mechanism

of action of opiates (see above) is correct, then opiates should lower
cAMP concentrations in these systems.

Havemann & Kuschinsky (1978)

measured cAMP levels in striatal tissue of rats in vitro, in the
absence and presence of opiates.
morphine (500 nM - 50

~M)

Slices of striata incubated with

accumulate less cAMP than slices incubated

32
without drugs.

This effect is not observed in slices incubated with
~M)

both morphine (SO

and naloxone (50

~M).

The decrease in the

accumulation of cAMP after incubation with morphine (500 nM) (33%) is
approximately the same as the decrease observed after incubation with
morphine (SO

~M)

(26%).

A change in the cAMP concentration in slices

incubated with opiates could result from drug-induced alterations in
the activity of either adenylate cyclase or cAMP phosphodiesterase.
Because incubation with morphine (20-50

~M)

also lowers (by about 20%)

cAMP levels in cell-free homogenates of striata in the presence of IBMX
(1 mM), Havemann & Kuschinsky believe the drug is altering cAMP
synthesis.
These results in striatal tissues agree with the prediction based
on Collier's hypothesis, as do the results of other experiments with
homogenates of rat cortex and hypothalamus (Tsang, Tan, Henry & Lal,
1978).

Other experiments with brain homogenates, slices or mince

systems have not yielded results in agreement with this prediction (for
example, Tell, Pasternak & Cuatrecasas, 1975; Katz & Catravas, 1977;
Tang & Cotzias, 1978).
genates and

sl~ces

Such discrepancies in results from brain homo-

may reflect species or regional differences.

But

more importantly, these biochemical measurements cannot directly relate
any opiate-induced changes in neuronal activity with changes in cyclic
nucleotide levels in those same neurons.

Morphine may alter cAMP

levels in brain tissue because of biochemical events subsequent to
alterations in resting or active membrane properties, or even by a nonspecific action on metabolism.

For example, morphine (20

~M-

2 mM)

alters cAMP formation in mouse prostate glands in a dose-related manner
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(Thomas, Dombrowsky, Mawhinney & Sharifi Hossaini, 1975), presumably by
an action unrelated to neuronal opiate receptors.
1.44

Experiments with neuroblastoma x glioma cells
Cells of the neuroblastoma x glioma line NG108-15 exhibit the

properties of neurons and possess opiate receptors; opiates bind to
these sites with the same relative affinities as they bind to rat brain
homogenates (Klee & Nirenberg, 1974).

Morphine decreases both basal

and prostaglandin-elevated cAMP levels in intact hybrid cells and
inhibits adenylate cyclase activity in cell homogenates
1975b; Traber, Fischer, Latzin & Hamprecht, 1975).
blocked by concurrent incubation with naloxone.

(Sharma~

al.,

These actions are

Furthermore, long-term

incubation of these cells in morphine (Sharma, Klee & Nirenberg, 1975),
enkephalin (Lampert, Nirenberg & Klee, 1976) or endorphin extracted
from the pituitary (Goldstein, Cox, Klee & Nirenberg, 1977) causes a
compensatory increase in adenylate cyclase activity which tends to
overcome the initial inhibition.

After this compensation has occurred,

removal of the opiate produces a large increase in the activity of the
cAMP system

t~

a level greater than before drug incubation.

These

phenomena have been described as the molecular basis for tolerance and
dependence to opiates (Sharma et al., 1975a).

Sodium fluoride, which

activates basal adenylate cyclase activity and uncouples the enzyme
from the hormone-receptor complex, abolishes the difference in enzyme
activities between control cells and cells incubated with morphine.
Opiates appear to increase the abundance of a high activity form of the
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enzyme (Sharma, Klee & Nirenberg, 1977).
The effect of opiates on the biochemistry of the NG108-15 cells
is not specific, as stimulation of both muscarinic cholinergic (Traber,
Fischer, Buchen & Hamprecht, 1975) and a-adrenergic (Traber, Reiser,
Fischer & Hamprecht, 1975) receptors inhibits the activity of adenylate
cyclase.

Long-term incubation of the cells with carbachol or norepi-

nephrine produces a compensatory increase in adenylate cyclase activity
(Klein, Nathanson & Nirenberg, 1976; Sabol & Nirenberg, 1977), just as
is seen with incubation in opiates.
Do the results obtained from the neuroblastoma x glioma hybrid
cells pertain to the action of opiates in other neuronal systems?

The

NG108-15 cells are tumor cells that differ in unknown ways from differentiated neurons.

They lack the synaptic connections of neurons in

their natural environment.

The cyclic nucleotide system in these cells

responds in general to an inhibition of its activity with a compensatory hypertrophy, whether the initial inhibition is produced by an
opiate, adrenergic or cholinergic agonist (see above).
specificity of the response is questionable.

Thus the

Nonetheless, it repre-

sents a biochemical correlate, though not necessarily the specific
mechanism, of opiate tolerance and dependence in these cells.

Some

form of physiological compensation must be occurring in neurons in
response to chronic treatment with opiates.

The involvement of the

cyclic nucleotide system in this compensation needs to be studied in
different types of neurons at central and peripheral sites.
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1.5

Role of the calcium ion in the actions of opiates on neurons
The calcium ion is a key regulator of major functions of neurons,

including cellular metabolism, membrane properties and transmitter
release.

An essential role for the calcium ion as an intermediary of

the actions of opiates on neurons has been hypothesized (Kaneto, 1971;
Sanghvi & Gershon, 1977; Ross, 1978).

The effects of altered calcium

ion concentration on actions of opiates and the effects of opiates on
calcium levels and metabolism in brain tissue form the basis of this
hypothesis.·
1.51

The effect of calcium ion on the actions of opiates
The potency of morphine in producing antinociception is lower in

mice that have received an injection of calcium ion by the intraventricular route.

On

the other hand, morphine is more effective in mice

that have been injected with the calcium chelator EGTA (Kakunaga,
Kaneto & Hano, 1966; Harris, Loh & Way, 1975).

These results have been

interpreted to suggest that the antinociceptive action of morphine is
mediated by a decrease in the availability of calcium at some neuronal
site, and that this deficiency can be overcome by administering high
doses of calcium.
Are there alternative explanations for the apparent antagonism by
calcium of the antinociceptive activity of morphine?

Calcium adminis-

tered into the ventricular system of the brain produces sleep and
anaesthesia in some species; these behavioral effects could mask the
action of morphine (see Kaneto, 1971).

Also, a physiological antagon-
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ism of the action of morphine by calcium may occur at the same or different anatomical sites.

Increased concentrations of extracellular

calcium ion have two important actions on neuronal activity:

stabili-

zation of the membrane (Koketsu, 1969) and enhancement of transmitter
release (Rubin, 1970).

Either or both could antagonize the neuronal

actions of morphine without involvement of a calcium link in those
actions.
In in vitro preparations containing neurons that bear opiate
receptors, opiates can inhibit nerve-evoked muscle contractions,
depress transmitter release or alter the electrophysiological properties of neurons.

The isolated guinea-pig ileum is an example of a

tissue in which all three of these actions of opiates are readily
demonstrable.

The effect of changing the external concentration of

calcium ion on each of these actions of opiates has been tested.

In

these experiments, a decrease in the effectiveness of morphine in
tissues superfused with solutions containing increased concentrations
of calcium ion is interpreted to mean that calcium is antagonizing the
effect of morphine.
The inhibition by morphine of nerve-mediated muscle contractions
of the guinea-pig ileum is reduced in tissues maintained in calcium
(5 roM) compared to tissues maintained in calcium (2 roM) (Heimans, 1975).
Opmeer & Van Ree (1979) also observed a lowered effectiveness of morphine in guinea-pig ilea maintained in high calcium (5.08 roM) rather
than normal calcium (2.54 roM) solutions.

In these experiments calcium

may be altering the response of the muscle by increasing the efficiency
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of excitation-contraction coupling.

The measurement of evoked trans-

mitter release in solutions of varying calcium ion concentration
eliminates problems associated with direct actions of calcium on
muscle.

In a preliminary study, Nutt (1968) observed no change in out-

put from strips of guinea-pig intestine maintained in calcium ion
concentrations varying over a 10-fold range.

But Sawynok & Jharnandas

(1979) do see a lesser degree of inhibition by morphine of evoked
acetylcholine release from strips of longitudinal muscle-myenteric
plexus if the latter are superfused with three times the normal calcium
ion concentration.

A similar effect occurs in solutions containing the

calcium ionophore A23187.

A puzzling aspect of this report is that the

amount of transmitter released in response to nerve stimulation was the
same in high (7.5 mM) calcium as in normal (2.5 mM) calcium.

Such a

large increase in calcium would be expected to enhance stimulussecretion coupling.
Opiates still inhibit the firing of single myenteric neurons in
solutions that contain no added calcium ion (Dingledine & Goldstein,
1976; Williams & North, 1979), arguing against an essential role for
the divalent cation in this action of opiates.

Thus even in the same

tissue the effect of calcium differs, depending on how the action of
opiates is measured.

The myenteric plexus is a complex neuronal

assembly in which the release of acetylcholine from the autonomic
neurons innervating the longitudinal smooth muscle could be influenced
in many ways and controlled at multiple sites.

A more desirable system

for the study of the calcium-opiate interaction is a simple preparation
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in which actions of calcium at loci other than on the neurons with
opiate receptors can be minimized or discounted.
1.52

The effect of calcium ion on the binding of opiates
Calcium ion could antagonize the actions of opiates in both in

vivo and in vitro experiments by inhibiting the binding of opiates to
neuronal receptors.

3
The stereospecific binding of both [ H]-dihydro-

3
morphine (DHM) and [ H]-naloxone to brain homogenates is significantly
less in solutions containing calcium ion than in solutions containing
zero calcium (Pert & Snyder, 1973b; Hitzemann, Hitzemann & Loh, 1974).
3
But the stereospecific binding of [ H]-DHM decreases by no more than
20% with a twenty-fold increase in the calcium ion concentration (1 to
20 mM); in the physiologically relevant range of calcium ion concen3
trations (1-5 mM), the amount of [ H]-DHM bound varies by no more than
10% (Pert & Snyder, 1974).

Thus the binding of opiates to neuronal

membranes does not appear to be a major locus of interaction with the
calcium ion.
1.53

Effects of opiates on calcium levels and fluxes
The calcium content of whole brain is reduced in mice that have

received a large subcutaneous dose of morphine (100 mg/kg but not 20
mg/kg) (Shikimi, Kaneto & Hano, 1967).

The same effect occurs in rats

that have been injected with morphine (25 mg/kg) (Yamamoto, Harris,
Loh & Way, 1978), although antinociception can be produced in these
animals by much lower concentrations of morphine.

The effect of
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morphine administration on calcium levels in brain is dose-related,
stereospecific and reversed by naloxone (Cardenas & Ross, 1975).

The

calcium loss is localized to synaptosomal fractions (Cardenas & Ross,
1976; Harris, Yamamoto, Loh & Way, 1977).

Animals that have received

prolonged morphine treatment (by pellet implantation) have higher
calcium levels in the synaptosomal fractions of their brains (Yamamoto
~

al., 1978) and an increase in the amount of radioactive label found

in isolated nerve ending fractions after the in vivo administration of
labelled calcium ion (Harris et al., 1977).

These investigators

believe that the nerve endings compensate for an initial depletion of
calcium caused by the acute administration of opiates.

This compensa-

tion takes the form of an increase in the content of calcium at these
sites.
Several problems are associated with this interpretation of these
results.

Firstly, morphine is not the only centrally active drug

which, when administered to animals, alters brain calcium levels.
Ethanol and reserpine also cause an apparent depletion of brain calcium,
although pentobarbital does not (Ross, Medina & Cardenas, 1974);
Calcium levels in guinea-pig brain stem are also altered during either
the excitation or the sleep produced by central stimulants or depressants respectively.

General alterations in brain functional activity

thus can change the distribution and content of calcium in the brain
(see Kaneto, 1971).

Secondly, acute administration of morphine (intra-

peritoneal injection of 6-100 mg/kg) decreases calcium levels to an
equal extent in eight different brain regions (Cardenas & Ross, 1975).
There is no correlation between the density of opiate binding sites and
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the extent of depletion of calcium in a given region.

Mice that have

received morphine have an equal decrease in the calcium content of the
striatum, an area rich in binding sites, as in the cerebellum, an area
practically devoid of opiate binding sites (Kuhar et al., 1973).

The

in vivo administration of morphine thus lowers calcium levels even in
neurons that do not bear opiate receptors.

One may argue that the

calcium effect observed in vivo is likely to be the result of a general
change in the functional state of the brain which has been elicited by
the administration of morphine.
(1971) .

This is the idea proposed by Kaneto

One possible mechanism is related to the respiratory depres-

sion caused by morphine.

Morphine in vivo increases the pco , causing
2

a decrease in the pH of the brain.

An increase in the extracellular

concentration of hydrogen ions can decrease the calcium content of
nerve (Baker & Honerjager, 1978).
Anionic groups of the proteins and phospholipids of cell membranes attract and bind cations such as calcium.

Narcotics inhibit the

binding of calcium to phospholipids in vitro, but high concentrations
(600

~M)

action.

are required and other centrally active drugs share this
The e.ffectiveness of a given drug correlates with its degree

of ionization (Mule, 1969).

Isolated synaptic membranes prepared from

whole rat brain minus cerebellum bind radiolabelled calcium ions
45

C ca++) with high affinity

CKU = 840

nM).

Low concentrations of

levorphanol (0.5-10 nM) added to the incubation mixture non-competitively inhibit this binding, an effect that is stereospecific and
blocked by naloxone (10 nM) (Ross & Cardenas, 1977).

Both the initial
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rate and the maximal level of uptake of
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ca++ into homogenates of

whole mouse brain are lower if morphine or levorphanol (but not dextrorphan) are added to the incubation mixture or if the homogenates are
prepared from mice pretreated with a single injection of morphine
(10 mg/kg).

In homogenates prepared from animals that have been chron-

ically exposed to morphine (pellet implantation), the time required for
maximal uptake of calcium is shortened, whereas the maximum level of
uptake is not changed (Guerrero-Munoz, Guerrero & Way, 1978).

This

study does not distinguish between calcium uptake (energy dependent)
and binding (no requirement for metabolic energy) and the relative
effect of morphine on each.
synaptosomes measured
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Therefore similar experiments using lysed

ca++ uptake in the presence and absence of ATP

(Guerrero-Munoz, Guerrero & Way, 1979).

Incubation in morphine de-

creases uptake only in the presence of ATP; this suggests that morphine
inhibits active uptake of calcium by synaptosomes.

The postulated

inhibition by morphine of calcium uptake into a resting nerve terminal
may not be relevant to any actions of morphine in inhibiting stimulusevoked transmitter release.

It is consequently of interest that

incubation witp levorphanol (100 nM) also reduces calcium uptake in
synaptosomes that have been depolarized by a solution containing high
potassium (50 mM) (Ross, 1978).
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1.6
1. 61

Neuro-effector transmission in the mouse vas deferens

Anatomy
The smooth muscle of the mouse vas deferens is innervated by the

sympathetic branch of the autonomic nervous system via the hypogastric
nerve.

Preganglionic sympathetic fibers in the hypogastric nerve

synapse in ganglia located close to the vas deferens:

this organ is

thus innervated by short adrenergic neurons (Sjostrand, 1965).

Like

most hollow ?rgans, the vas deferens consists of inner circular and
outer longitudinal layers of smooth muscle.

The following description

of the fine structure of the muscle cells and their innervation in the
vas deferens of the mouse is a composite of the work of Lane & Rhodin
(1964) and Jones & Spriggs (1975b).
(100-300

~m)

Individual muscle cells are long

and thin (diameter less than 10

branching and anastomosing bundles.

~m)

and are arranged in

Adjacent cells often appear to

interlock by "peg and socket" structures - an evagination of one cell
fits into an invagination of the next.

Tight junctions ("nexuses" -

apposing membranes fused) , which are low resistance pathways for flow
of electrical current between cells, are infrequently found in the
mouse vas deferens (Yamauchi & Burnstock, 1969).

Thus although

electrophysiological studies reveal electrotonic coupling among the
cells (see below), the structures which allow such coupling have not
yet been identified.
The fine unmyelinated sympathetic fibers run for long distances
through the smooth muscle before terminating.

Large bundles of axons
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(about 8 axons/bundle) enclosed in Schwann cell sheaths run between the
muscle bundles.

Smaller bundles of axons, sometimes with an incomplete

sheath, are seen between individual muscle cells.

Axons which are

devoid of a Schwann cell sheath eventually emerge from these bundles
and run singly between cells; these axons often lie in an indentation
of a cell or are completely enclosed within smooth muscle cytoplasm
(Furness & Iwayama, 1971).

The single axons are varicose, with alter-

nate constrictions and dilatations of their diameter at regular intervals.

The dilated areas, or nodes, contain numerous synaptic vesicles

and some mitochondria and are presumed to be the sites of transmitter
release.

Nerve varicosities often closely approach the muscle cells;

neuromuscular clefts of 7-8 nm are common.

All cells appear to be

innervated by one or more such close contacts; this is not the case for
all smooth muscle organs (see Burnstock, 1970).

No postsynaptic

specializations of the muscle cells are evident.
Three types of synaptic vesicles are seen within the axonal
varicosities.

Small dense-core (granular) vesicles are much more

numerous than small electron-lucent (agranular) vesicles:

approxi-

mately 73% of axons contain small granular vesicles only, 22% both
agranular and granular vesicles, and 5% agranular vesicles only.

A

proportion of the axon profiles also contain one or a few large
granular vesicles.

Small granular vesicles are believed to be associa-

ted with the storage of noradrenaline, whereas agranular vesicles are
identical to those seen at the skeletal neuromuscular junction and are
presumed to be cholinergic.

The contents of large granular vesicles

are unknown (Burnstock, 1970).
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Anatomical studies implicate noradrenaline as the transmitter of
the mouse vas deferens.
high (about 5

~g/g

The noradrenaline content of the tissue is

of tissue) (Sjostrand, 1965).

The vas exhibits a

dense catecholamine fluorescence which is reduced or abolished by pretreatment of the mouse with 6-hydroxydopamine (Furness, Campbell,
Gillard, Malmfors, Cobb & Burnstock, 1970), a toxin which is taken up
into noradrenergic nerve terminals, displaces noradrenaline from the
vesicles and subsequently causes degeneration of the nerve terminal
(Thoenen & Tranzer, 1968).

The majority of axons in the mouse vas

deferens contain small granular vesicles which are the predominant type
in mammalian sympathetic nerves.

The dense core of these vesicles is

best observed by permanganate fixation of the tissue (Furness et al.,
1970) or by pretreatment of the animal with 5-hydroxydopamine (Chiba,
1973).

The latter substance is a marker for adrenergic nerve terminals

(Tranzer & Thoenen, 1967).

A small number (7-8%) of axons found in the

mouse vas deferens may be cholinergic (Jones & Spriggs, 197Sa).

These

axons contain small agranular vesicles and acetylcholinesterase
reaction product on their surface membrane.
1.62

Mechanical responses
Some investigators have expressed doubt that noradrenaline is the

neurotransmitter of the vas deferens (guinea-pig:
1971; mouse:

Jenkins, Marshall & Nasmyth, 1977).

Ambache & Aboo Zar,
The basis of the

argument against noradrenaline as the transmitter is three-fold.
First, the muscle is insensitive to exogenous noradrenaline.

Muscle

contractions evoked by adding noradrenaline to the organ bath rarely
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compare in amplitude to those evoked by stimulation of the intramural
nerves.

Secondly, the nerve-mediated twitch response of the muscle is

reduced by exogenous noradrenaline.

And, finally, neurotransmission is

insensitive to blockade by classical a-adrenoceptor antagonists, especially phenoxybenzamine.

Each of these results can be explained with-

out abandoning the noradrenaline hypothesis.

The insensitivity to

exogenous noradrenaline could result from the close packing of the
muscle cells.

The effect of noradrenaline on the smooth muscle peaks

within 30 s, yet in this time the noradrenaline would diffuse into only
about 15% of the extracellular space (Jones & Spriggs, 1975b).

Trans-

mural stimulation of the nerves effectively activates all of the smooth
muscle cells.

Also, extra-junctional rather than junctional regions of

the postsynaptic cells would be more accessible to exogenous substances.

By analogy with skeletal muscle, junctional regions in the

vas deferens may be more sensitive to transmitter.

Low concentrations

of exogenous noradrenaline inhibit the nerve-mediated twitch response
of the muscle by an action on nerve terminals.
possess presynaptic a-adrenergic receptors:

Sympathetic nerves

a-adrenergic agonists

inhibit and a-adrenergic antagonists potentiate the nerve-evoked release of noradrenaline (see Starke, 1977).

In the mouse vas deferens,

noradrenaline is less potent in this action than clonidine, but the
action of both is blocked by yohimbine (Marshall, Nasmyth, Nicholl &
Shepperson, 1978).

Yohimbine is an a-adrenergic antagonist that in low

concentrations selectively blocks presynaptic receptors.

Furness

(1974) explains that the ineffectiveness of the a-adrenergic antagonist
phenoxybenzamine in blocking the nerve-mediated twitch may be the
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result of the closeness of the neuromuscular contacts and the nonspecificity of the drug.

Thus the highly charged phenoxybenzamine

molecule may have difficulty penetrating to the actual site of neurotransmission, which in the mouse vas deferens is well insulated (see
above).

Also, phenoxybenzamine has other actions besides postsynaptic

a-adrenergic receptor blockade, such as antagonism of noradrenaline
uptake, inhibition of the enzymatic breakdown of noradrenaline and
potentiation of noradrenaline release by blocking the inhibitory presynaptic a-adrenergic receptors.

These four latter actions would tend

to increase rather than decrease the efficacy of adrenergic transmission.

Furthermore, high concentrations of another a-adrenergic

antagonist, phentolamine-- 53

~M:

Jones & Spriggs (1975b); 360

~M:

Henderson (1974) -- do abolish the responses of the vas to both transmural nerve stimulation and exogenous noradrenaline.
Other findings from organ bath physiology experiments further
implicate noradrenaline as the transmitter.

The mouse vas deferens

takes up and stores labelled noradrenaline, and the amount of label
released upon nerve stimulation depends on the stimulation frequency
and is related to the contractile response of the muscle (Farnebo &
Malmfors, 1971).

Muscle responses to transmural stimulation are

inhibited by guanethidine (Jones & Spriggs, 1975b) and abolished by
bretylium but then restored by amphetamine (Henderson, 1974).

Also, no

nerve-mediated contractions can be elicited in vasa from mice pretreated with 6-hydroxydopamine (Jones & Spriggs, 1975b).

These are

typical pharmacological responses of an adrenergically innervated organ.
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1.63

Electrophysiology
Passive and active membrane responses of smooth muscle can be

observed by intracellular recordings from individual cells.

Junction

potentials, short-lived changes in membrane potential in response to
interaction of transmitter with receptors on the smooth muscle membrane, were first described for the vas deferens of the guinea-pig by
Burnstock & Holman (1961) and for the vas deferens of the mouse by
Holman (1967).

The junction potentials of the vas deferens are depol-

arizing and can be elicited by either stimulation of the hypogastric
nerve or by field stimulation of intramural nerves.

The excitatory

junction potentials (e.j.ps) of the mouse vas deferens can be evoked by
both orthodromic and antidromic activation of the intramural nerves,
indicating that transmitter is released from the varicosities along
the length of the axon, and not just from axon terminals (Furness,
1970).

The time to peak (rise time) of the e.j.p. is 10-20 ms, and the

duration is 100-250 ms.

The amplitude of the evoked e.j.p. is graded

with stimulus strength.

Increasing the stimulus strength recruits more

nerve fibers; up to 15-22 fibers may contribute to the e.j.p. in a
given cell (Furness, 1970).

Holman (1967 & 1970) observed that spon-

taneous junction potentials occur with a variable frequency in the
mouse vas deferens.

Their amplitudes range from just above the noise

level of the recording system (about 1 mV) to about 20 mV.

These

potentials are presumed to result from the spontaneous release of
transmitter from the adrenergic nerve varicosities because they persist
in the presence of tetrodotoxin (Hashimoto, Holman & McLean, 1967).
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The variation in amplitude may be a consequence of transmitter release
at different distances from the impaled cell, into synaptic clefts of
differing geometry.

The actual amount of transmitter released may

also vary.
E.j.ps of smooth muscle have been compared to end plate potentials (e.p.ps) of skeletal muscle.

E.j.ps are assumed to result from

an increase in conductance of the smooth muscle membrane to one or more
ions, just as the e.p.p. is the consequence of current flowing due to
an increased conductance of the skeletal muscle fiber membrane to
sodium and potassium ions (Takeuchi & Takeuchi, 1960).

Experiments

attempting to define the mode of action of noradrenaline on the postsynaptic membrane are difficult because of the syncytial nature of
smooth muscle.

Smooth muscle cells are, to a greater or lesser extent,

electrotonically coupled to one another.

Caution is warranted in

interpreting data obtained by intracellular recording from one point in
a syncytium (Tomita, 1970; Holman & Nield, 1979).

The current applied

at one point, for example from a microelectrode placed in a single
smooth muscle cell, spreads in three dimensions.

The current density

decreases rapidly with distance from the current source, as the current
is shunted through the low electrical resistance of the surrounding
membrane.

The area of membrane increases as approximately the cube of

the distance from the point of current application.

Only a small

amount of the current passes across the membrane of the impaled cell.
Thus attempts to demonstrate an increased conductance of the smooth
muscle membrane during an e.j.p. have been unsuccessful because the
e.j.p. recorded in a given cell is largely or entirely the result of
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electrotonic spread of depolarization from neighboring cells (Holman,
1970).

Similarly, the amplitude of the e.j.p. in a given cell is not

altered by changing the membrane potential of that same cell by intracellular injection of current (Holman, 1967).

If, however, the entire

smooth muscle membrane is depolarized with exogenous noradrenaline
(Furness, 1970) or potassium sulphate (Holman, 1970), the amplitude of
the e.j.p. is reduced.

Interpretation of data obtained in this manner

is difficult because these treatments alter the properties of the presynaptic nerve terminals as well as the postsynaptic muscle membrane.
If the smooth muscle membrane is depolarized to + 20 mV by a combination of potassium sulphate and intracellular current injection, the
polarity of spontaneous potentials is reversed (Holman, 1970).

This

result may indicate that noradrenaline is increasing the permeability
of the membrane to sodium and at least one other ion.
E.j.ps of smooth muscle have also been compared to e.p.ps of
skeletal muscle in terms of the quantal nature of transmitter release.
The e.p.p. results from the simultaneous release from the motor nerve
terminal of many packets (quanta) of transmitter of approximately the
same size (del Castillo & Katz, 1954).

Transmitter release from

autonomic nerves is also assumed to be quantal, but direct proof is
lacking.

Blakeley & Cunnane (1979) provide some evidence for packeted

release of transmitter in the guinea-pig vas deferens.

They found that

the evoked e.j.p. has intermittent peaks in its rate of rise which are
superimposed on a regular, non-intermittent component of the voltage
change.

In some cells, these peaks or "discrete events" have preferred
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amplitudes which are whole number multiples of their smallest amplitude.

Furthermore, a few cells demonstrate spontaneous e.j.ps that are

of the same amplitude and time course as a discrete event recorded in
that same cell.

The spontaneous potential and the discrete event are

assumed to result from the release of a packet of transmitter from the
same varicosity.
nents:

Thus the rising phase of the e.j.p. has two compo-

discrete events which represent the packeted release of trans-

mitter directly onto the impaled cell, and a slow non-intermittent
component which represents the electrotonic spread of depolarization
from neighboring cells.
1.64

Effects of opiates
Intracellular recording of an e.j.p. is a sensitive method of

assaying the small amount of transmitter released from the noradrenergic nerve varicosities in response to a single stimulus to the intramural nerves.

The inhibition of evoked transmitter release in the

mouse vas deferens by opiates is reflected in the depression of e.j.p.
amplitude by normorphine (Henderson & North, 1976).
not prevent

th~

Normorphine does

depolarization of the smooth muscle cells by added

noradrenaline, thus confirming the presynaptic location of the opiate
receptors.
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1.7

Research objectives

The object of this study is to examine the depression by opiates
of the amplitude of the evoked e.j.p. in the mouse isolated vas
deferens.

The study will investigate factors that modify the opiate-

induced depression of e.j.p. amplitude and hence will try to clarify
the mechanism by which opiates decrease transmitter release by their
action on nerve terminals.
(1)

The specific aims are:

to study the changes that occur in neuro-effector transmission
in the mouse vas deferens after chronic exposure to morphine.

(2)

to examine the role of cyclic nucleotides and the calcium ion in
the acute depressant action of opiates on transmitter release in
the mouse vas deferens.

2.
2.1

METHODS

Preparation of the tissue

Male mice (25-40 g) of the CF-1 strain (ARS, Madison, WI) were
killed by a blow to the head.

Both vasa deferentia were dissected

free from the pelvic cavity and placed in a Petri dish filled with
Krebs solution.

Vasa are closely invested with a fine connective

tissue sheath containing the nerve and blood supply to the organ.
The portion of the sheath containing the main artery was removed.

Both

ends of the tissue were tied with fine silk thread (6-0) in order to
pull them through ring-shaped stimulating electrodes (see below).
The tissue was transferred to a bath constructed of perspex.
This bath had a long rectangular channel filled with a silicone rubber
resin (Sylgaard, Dow Corning).

The bath was secured to the stage of a

dissection microscope with modeling clay.

The vas deferens was placed

at right angles to the length of the Sylgaard-filled trough and the
central portion was pinned.

A section of the vas was first secured by

four large pins arranged in the form of a square or rectangle (2 mm x

2-3 mm); the

~issue

was stretched by this procedure so that it pre-

sented a flat surface as opposed to the rounded contour of unpinned
tissue.

The close investment of fine connective tissue of the pre-

senting surface was removed with the aid of fine jeweler's forceps.
Small pins cut from tungsten wire were used to further stretch and
immobilize the portion of the tissue delineated by the four larger
pins.
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Platinum ring electrodes with an inner diameter approximating the
diameter of the vas deferens were placed on either side of the tissue.
Each end of the vas was threaded through a ring electrode, and the
electrode positioned about 2-3 mm above, and slightly to the side of,
the pinned out portion of tissue.

A wick of tissue paper kept moist

that portion of the muscle which led to the electrode.
The tissue was superfused with Krebs solution of the following
composition (mM):

NaCl 118, KCl 4.75, KH Po 0.93, CaC1 2.54,
2 4
2

MgC1 ·7H o 1."19, glucose 11 and NaHC0 25.
2
2
3
ously gassed with 95%

o2

and 5%

co 2

This solution was continu-

in its main reservoir.

It then

was pumped at a constant flow rate of 1.5 ml/min through a series of
three-way taps, through the tubing of a Gilson pump and finally through
fine polyethylene tubing.

The latter tubing was, before leading to the

tissue bath, invested with a jacket containing heated water.

The tem-

perature of the Krebs solution at the site of recording was 35-37° C.
Drugs or solutions of varying ionic composition were applied to
the tissue by superfusion.

Each drug or solution was contained in a

separate reservoir and attached to one of the three-way taps.

Turning

the tap changed the Krebs solution from the standard solution to
another which differed only in its content of drug or in its ionic
composition.

The "dead time" or the time interval between the turning

of a tap and the appearance of the new solution at the tissue varied
from 40 s to 1.5 min (depending on tap location, tubing lengths and
pump speed).
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2.2

Electrical recording

Glass capillary tubing (1.0 or 1.2 mm outside diameter), pulled
to a fine tip by a micropipette puller of the horizontal type
(Industrial Science, model Ml), was used for recording from single
smooth muscle cells.

The microelectrode was filled with 2M KCl and

attached to a Narishige micromanipulator.

A fine chloridized silver

wire was inserted into the filled microelectrode.

The electrical sig-

nal from the silver wire electrode was magnified lOOX by the pre-amplifier (Nihon-Xohden model MZ-3B) and displayed on two oscilloscopes
(Tektronix 502A and 535A).
DC-coupled.

The amplifiers on the oscilloscopes were

The trace on the 502A oscilloscope was photographed with a

Grass kymograph camera (model C4R) on 35 mm Tri-X Pan film (EastmanKodak).

The second oscilloscope was used for visual observation.

The resistance of the microelectrode was measured by means of a
Wheatstone bridge circuit (Figure 1) as described by Araki & Otani
(1955).

The bridge was balanced, that is, the points C and D were iso-

potential, if the current flow was equal through each of the parallel
arms

~CB

and ADB.

This occurred if R /R
1 2

= R3 /R4 . The bridge was

calibrated by substituting known resistances for R and adjusting R
2
4
until no current flowed between points C and D (current trace was monitored on the oscilloscope).

The resistance of a given microelectrode

could be measured by dialing to the resistance (R ) which balanced the
4
bridge.

Electrodes of resistance 50-80

stable recordings.

MQ

were most useful for
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Figure 1.

Diagram of Wheatstone bridge circuit.

The resistances of

microelectrodes for intracellular recording were measured using the
Wheatstone, bridge circuit illustrated.
limiting resistor.

R was a 1,000 Mn current
1

The resistance of the microelectrode (R ) was
2

another arm of the bridge:
grounded the tissue bath.

This arm also contained the lead which
The rest of the bridge consisted of a

10,000 n variable resistor which remained fixed at a given value
(R ), and a 1,000 n variable resistor which was adjustable (R ).
4
3
test voltage was

~pplied

across points A and B of the circuit.

A
A

signal related to the potential difference between points C and D was
amplified and monitored on an oscilloscope.
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2.3

Impalement of the smooth muscle cells

The microelectrode was lowered until it just touched the surface
of the most superficial layer of smooth muscle.

This position was

indicated by a sudden unbalancing of the bridge as the electrode tip
encountered the resistance of the tissue.

The microelectrode was

driven through the tissue by a succession of advancements by the micromanipulator, interspersed with gentle tapping of the micromanipulator
or table.

Cells were impaled by either a gentle tap or by a short

duration, sudden increase of the amplifier's capacity compensation.
Successful impalement was indicated by a drop in the DC potential of
60 mV or greater.
The resting membrane potentials of cells were measured by sudden
withdrawal of the recording electrode into the perfusing solution.
Measurements were made only for cells which showed stable resting
membrane potentials for longer than 10 min.
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2.4

Stimulation of the intramural nerves

The intramural nerves were stimulated by the platinum ring
electrodes with single rectangular pulses (500

~s

or 1 ms in duration);

these pulses were generated by a Grass stimulator (model S88) and were
isolated from ground.

The preparation was stimulated at 30 s intervals

because facilitation of e.j.p. amplitude is not evident at this frequency (Henderson & North, 1976).

The stimulus voltage was adjusted so

that the unfacilitated e.j.p. was between 10 and 25 mV (usually about
15 mV) in amplitude before measuring the effect of a drug that depressed the e.j.p.

These e.j.p. amplitudes were chosen because at

lower amplitudes the depressant action of a drug is less accurately
measured and at higher amplitudes non-linear summation (Martin, 1955)
may become important.

The initial e.j.p. amplitude was between 4 and

12 mV before addition of a drug which increased e.j.p. amplitude.
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2.5

Prolonged exposure to normorphine in vitro

After removing the vas deferens from the animal, the

tiss~es

were superfused with Krebs solution containing normorphine (300 nM).
After 1-5 h of this treatment, the effect of normorphine (1 and 3
on e.j.p. amplitude was tested.

The effect of naloxone (300 nM) on

the e.j .p. was tested after 5-8 h of superfusion with normorphine
(300 nM).

~M)
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2.6

Prolonged exposure to morphine in vivo

Vasa deferentia from some mice were exposed to morphine in vivo;
these mice were given 9 intraperitoneal injections of morphine sulphate
(doses of 40, 60, 80, 100, 120, 140, 140, 140 and 140 mg/kg) at 8 h
intervals.

The animals were killed 2 h after the final injection of

morphine and their vasa were rapidly removed and placed in Krebs solution containing normorphine (300 nM).

Experiments on vasa from

morphine-pretreated mice were completed within 5 h of removing the
tissue from

~he

animal.

The tissues from morphine-pretreated mice were maintained in
Krebs solution containing normorphine to approximate the in vivo condition in which morphine is continuously present (North & Karras, 1978a)
and to prevent the withdrawal and rapid loss of tolerance which occurs
in the mouse vas deferens upon
Krebs solution (Cox, 1978).

was~ing

the tissue with opiate-free

The reasons for using a concentration of

normorphine of 300 nM were two-fold.

Firstly, this concentration is

similar to the concentration used by Schulz & Herz (1976) in their
study of morphine tolerance in the guinea-pig ileum.

They found that

normorphine (200 nM) ideally maintained tissues removed from morphinepretreated animals in a state of tolerance and dependence.

Secondly,

by maintaining a tissue in a concentration of 300 nM, a normorphine
dose-response curve can be completed without exceeding a 10
tration.

Morphine in concentrations above 10

~M

~M

concen-

inhibits noradrenaline

uptake in adrenergic nerves by an action unrelated to the opiate
receptor (Montel & Starke, 1973).
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2.7

Effects of cyclic nucleotides and phosphodiesterase inhibitors
The acute effects of the cyclic nucleotide cAMP and the dibutyryl

derivative of cAMP (dbcAMP), and the acute effects of the phosphodiesterase inhibitors IBMX and SQ 20,006 on the amplitude of the evoked
e.j.p. were determined.

The effect of normorphine on e.j.p. amplitude

was tested on tissues superfused with cAMP (1 mM) and on tissues superfused with the drug combination dbcAMP (500

~M)

and IBMX (50

~M).

The

2
5
2
5
effects of D-Ala -Met -enkephalinamide (DAEA) and D-Ala -D-Leu enkephalin (DADL) on e.j.p. amplitude were tested on tissues superfused
with both IBMX (500

~M)

and dbcAMP (250

~M).
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2.8

Effects of altered concentrations of calcium ion

The alteration of e.j.p. amplitude caused by halving or doubling
the normal calcium ion concentration (2.54 mM) was determined.

In

these solutions of varying calcium ion concentration, osmolarity was
maintained by adjusting the concentration of NaCl.

Dose-response

curves for the depression by normorphine of e.j.p. amplitude were
constructed for vasa maintained in ·calcium ion concentrations of 1.27

mM, 2.54 mM and 5.08 mM.
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2.9

Contractions of the vas deferens

A single vas deferens was suspended in an organ bath (volume
1.5 ml).

The tissue was washed with Krebs solution warmed to 37° C and

gassed with 95%

o2

and 5% C0 ; this solution was of the same ionic
2

composition as described above except for the omission of magnesium ion
(Hughes et al., 1975a).

Changes in tension of the vas deferens were

recorded isometrically.

Single stimulus pulses (voltage maximal, dura-

tion 1 ms, frequency 0.1 Hz) were generated by a Grass stimulator
(model S4K) ·and applied to the tissue across two platinum wire electrodes situated at the top and bottom of the organ bath.
effect of normorphine (100 nM - 30

~M)

The

on the responses of the muscle

to nerve stimulation was tested.
Dose-response curves for the contractile response to noradrenaline were constructed.

Noradrenaline doses were given in ascending

order at 12 min intervals.

Noradrenaline (1

~M-

1 mM) was applied in

the same location in the organ bath relative to the tissue and in the
same volume (13
requ~red

~1).

The largest concentrations tested (3 and 10 mM)

larger injection volumes.

Stock solutions of noradrenaline

in Krebs solution were made fresh daily and contained ascorbic acid
(100

~M).

In a few experiments a linear motion transducer was used to
record the changes in length of the vas deferens in response either to
field stimulation of the intramural nerves (as above) or to an
injection of noradrenaline or high potassium solution.
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2.10

Collection and analysis of data

The calibration of the oscilloscopes was periodically checked by
using a square-wave generator.

E.j.p. amplitudes _were measured by

projecting the oscilloscope traces recorded on film onto calibrated
graph paper by means of a film enlarger.

The percentage change in

e.j.p. amplitude in response to a drug or to a change in ionic composition of the Krebs solution was determined as follows.

After a

control period of four min or more, the tissue was superfused with drug
until the

~litude

of at least three consecutive e.j.ps remained

relatively constant (no trend toward an increase or a decrease in
amplitude was discernible).

For each drug application, a plot of

e.j.p. amplitude vs. time was drawn.

E.j.p. amplitudes during the

control period and during the time of maximum drug effect were determined by either drawing a line through the data points (estimated by
eye) or by averaging the measured amplitudes.

A drug effect was not

accepted unless at least a 50% reversal of the effect occurred upon
returning to control Krebs solution.
Results were analyzed by calculation of the mean, standard
deviation and standard error of the mean using standard formulae
(Goldstein, 1964).

Student's t test was used to compare the means of

two groups which received different experimental treatments.

One-way

analysis of variance (ANOVA) was used to compare the means of three or
more groups.

A p value greater than 0.05 was chosen to indicate

statistical significance.

65
2.11 Drugs
Drugs used were:

adenosine (Sigma), adenosine 3' ,5 1-cyclic

2
5
monophosphoric acid (Sigma), D-Ala -D-Leu -enkephalin (Biosearch),
21
2
5
6
D-Ala -Met -enkephalinamide (Peninsula), N , 0 -dibutyryl adenosine
3' ,5'-cyclic monophosphoric acid, sodium salt (Sigma), l-ethyl-4hydrazino-1H-pyrazolo(3,4-b)pyridine-5-carboxylic acid, ethyl ester,
hydrochloride (SQ 20,006) (Squibb), 1-methyl-3-isobutylxanthine
(Sigma), dl-noradrenaline hydrochloride (dl-arterenol) (Sigma),
morphine sulphate (Lilly), naloxone hydrochloride (Endo Laboratories)
and normorphine sulphamate (Dr. A. E. Jacobson).
Molar concentrations refer to the final bath concentration of
these substances.

3.
3.1

RESULTS

General observations

The results of the present study are based on recordings from 363
cells (152 mice).

Recordings from single cells of up to 3.5 h were

possible, although the usual duration of impalement was 20 min to 1 h.
The resting membrane potential of individual smooth muscle cells was
62.6

± 0.9

mV (mean+ s.e. mean, n

= 16).

E.j.ps evoked by field stimulation of the intramural nerves of
the vas deferens could be recorded in every cell successfully impaled;
their amplitudes were dependent on the stimulus strength.

At a fixed

stimulus duration, the stimulus voltage used to evoke an e.j.p. of a
given amplitude (about 15 mV) varied from one tissue to the next, and
among cells in the same tissue.
on:

The voltage for a given cell depended

the initial positioning of the platinum ring electrodes around the

muscle, the location of the cell relative to the electrodes, the position of the recording electrode and the depth of the Krebs solution
flowing through the tissue bath.
The time to peak amplitude for an e.j .p. was 25-45 ms, and the
time to decay to one-half the peak amplitude was 60-90 ms.

The rising

phase of the depolarization was steeper in slope and shorter in
duration than the falling phase (Figure 2).

In some cells graded

action potentials were observed; these events could occur on the rising
phase, peak or falling phase of an e.j.p.
66

If these potentials obscured
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Figure 2.

Photographs of excitatory junction potentials (e.j.ps).

Photographs of oscilloscope tracings illustrating the waveform and
time course of,an e.j.p., and the depression of e.j.p. amplitude by
normorphine.

In this cell, normorphine (1

amplitude ·by 68%,' from 22-mV to 7 mV.

~M)

decreased e.j.p.

This effect washed within 5

min of resuming superfusion with drug-free Krebs solution.
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the peak amplitude of the e.j.p. in a cell, the cell was not used for
experimentation.
Spontaneous junction potentials were observed in almost every
cell, although their frequency was markedly variable among cells and
tissues.
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3.2
3.21

Effect of opiates and opioid peptides

Normorphine
Normorphine (100 nM - 30

~M)

depressed the amplitude of the

evoked e.j.p. (Figure 2) but did not alter the resting membrane potential of the smooth muscle cells.

Any effect of a drug on membrane

potential would be obvious if the change were greater than 3-5 mV.
This effect of normorphine was maximal 4-8 min after the onset of drug
superfusion, and usually washed within 5-15 min of resuming superfusion
with

drug-f~ee

Krebs solution.

The magnitude of the depression of the

e.j.p. by normorphine was larger with higher concentrations of normorphine.

A composite dose-response curve for normorphine was constructed

by pooling results from many cells.

Because the duration of impale-

ments was variable, it was not always possible to test all concentrations of normorphine on the same tissue.

Occasionally, however, all

normorphine concentrations were tested even on a single cell.

The Ec

50

for normorphine (concentration that depressed the e.j.p. to 50% of its
control amplitude) was 570 nM (Figure 3).

An e.j.p. that was depressed

in amplitude by normorphine could be restored to its control amplitude
by increasing the stimulus voltage.
3.22

Normorphine at different stimulus strengths
Many of the experimental protocols of the present study involved

testing the effect of opiates or opioid peptides on vasa which have
been exposed to substances or ionic conditions which themselves altered
e.j.p. amplitude.

Under these conditions the stimulus strength was ad-
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Figure 3.
phine and
for

Dose-response curves for depression of e.j.p. by normoropi~id

peptides.

A comparison of the dose-response curves

depres~ion bf e.j.p: amplitude by normorphine (NOR), D-Ala 2-Met 5-

2
5
enkephalinamide (DAEA) and D-Ala -D-Leu -enkephalin (DADL).
represent + standard deviation.

Bars

Numbers in parentheses indicate the

number of individual cells tested at a given concentration.
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justed in order to obtain a control e.j.p. of approximately 15 mV in
amplitude before testing the effect of an opiate or opioid peptide.

It

was therefore necessary to investigate if the potency of normorphine
was dependent on the initial amplitude of the e.j.p. and on the stimulus strength necessary to evoke it.
1

~M)

Normorphine (100 nM, 300 nM and

was tested on both high amplitude and low amplitude e.j.ps, often

on the same cell or tissue.

The degree of depression of the high

amplitude e.j.ps (35 mV) was the same as the degree of depression of
low

amplitud~

e.j.ps (10 mV) by a given concentration of normorphine

when the results from many cells and tissues were pooled.
site results are summarized in Table la.
cell, normorphine (1

~M)

These compo-

Also, for a given individual

was equally effective in depressing the e.j.p.

regardless of the control e.j.p. amplitude in the range 9-38 mV
(Table lb).
3.23

Prolonged exposure to normorphine in vitro
Some vasa were incubated in Krebs solution containing normorphine

(300 nM) for 1-5 h, and the effect of higher concentrations of normorphine (1 and

3.~M)

on e.j.p. amplitude was then tested.

such an experiment is illustrated in Figure 4.
phine (3

~M)

An example of

The potency of normor-

in causing a depression of e.j.p. amplitude in vasa main-

tained in Krebs solution containing normorphine (300

ru~)

was not

different from its potency in vasa maintained in drug-free Krebs
solution.

Normorphine (1

~M)

was less effective in the vasa exposed to

opiate drug in vitro (Table 2).
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Table 1.

Effect of e.j.p. amplitude and stimulus voltage on

depression of e.j.p. by normorphine.
*Mean± s.e.
cells tested.

m~an.

(a) Composite results.

Numbers in parentheses indicate the number of

Depression of high amplitude e.j.p. vs. depression

of low amplitude 'e.j.p. was the same for all three concentrations
of normorphine (100 nM, 300 nM and 1
p>0.05).

~M)

(b) Results from three cells.

(Students's t test,
There was no change in the

degree of depression caused by normorphine (1

~M)

if tested on

e.j.ps of different amplitudes recorded in the same cell.

E.j.p.

amplitude was changed by increasing or decreasing the stimulus
strength.

75

Table 1.
(a)

Composite results
Amplitude of
e. j . p. (mV) *

Percent depression
of e.j.p.*

NORMORPHINE (100 nM):
Large amplitude e.j.p.

35.5 + 1.8 mV

-17 + 5.2% (7)

Small amplitude e.j.p.

10.4 + 0. 9 mV

-19 + 5.8% (6)

Large amplitude e.j.p.

35.3 + 1.2 mV

-39 + 5.0% (6)

Small amplitude e.j.p.

10.7 + 0.8 mV

-46 + 3.6% (6)

Large amplitude e.j.p.

34.0 + 2.1 mV

-73 + 3.2% (6)

Small amplitude e.j.p.

11.4 + 1.3 mV

-66 + 5.3% (6)

NORMORPHINE (300 nM):

NORMORPHINE (1 ].!M):

(b)

Individual cells

Cell II

4209-2

"
4279-2

"

"
4309-1

"

Stimulus
Voltage

Amplitude of
e.j .p. (mV)

Percent depression
of e.j.p. by
Normorphine (1 ].JM)

1.3
7.6

10
26

75
73

1.0
10.0
17.0

9
16
36

54
63
65

10.4
23.0

10
38

84
87

76

Figure 4.

Effect of normorphine (1 and 3

~M)

on e.j.p. after

prolonged superfusion with normorphine (300 nM) in vitro.
tissue had been

.maintain~d

This

in Krebs solution containing normor-

phine (300 nM) for 4 h at time zero, and normorphine (300 nM) was
also present throughout the recording period.
with normorphine (1

~M)

During superfusion

for 5 min, the e.j.p. was depressed by 50%.

During superfusion with normorphine (3
e.j.p. was depressed by 78%.

~M),

also for 5 min, the
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Table 2.

Effect of superfusion with drug-free Krebs solution vs. Krebs

solution containing normorphine (300 nM) on depression of e.j.p. by
normorphine (1 and 3

~M).

The depression by normorphine (1 and 3

~M)

of amplitudes of evoked e.j.ps was measured in vasa maintained in drugfree Krebs solution or in vasa maintained in Krebs solution containing
normorphine (300 nM) for 1-5 h.

*Mean+ s.e. mean.

Numbers in paren-

theses indicate the number of cells tested at a given concentration.
Values from vasa maintained in drug-free Krebs solution and values from
vasa

maintai~ed

in normorphine-containing Krebs solution were signifi-

cantly different for normorphine (1
not for normorphine (3

~M)

(Student's t test; p<O.Ol) but

~M).

Percent depression of e.j.p.*
Nor (1

~M)

Nor (3

~M)

Vasa maintained in drugfree Krebs solution

66 + 1.5% (16)

78 + 1.8%

(8)

Vasa maintained in Krebs
solution containing
normorphine (300 nM)

54 + 2.1%

76 + 1.5%

(8)

(8)
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3.24

DAEA
DAEA (10-300 nM) decreased the amplitude of the e.j .p.

DAEA did

not alter the resting membrane potential of the smooth muscle cells.
The effect of DAEA on e.j .p. amplitude was maximal within 4 min of the
onset of drug superfusion, and quickly reversed (4-6 min) after drug
washout.

The dose-response curve for the depression of the e.j.p. by

DAEA is shown in Figure 3; the EC
3.25

50

for this action of DAEA was 50 nM.

DADL
DADL (300 pM- 3 nM) decreased the amplitude of the evoked e.j .p.

but did not change the resting membrane potential of the smooth muscle
cells.

Although the maximum effect of this peptide consistently

occurred within 4-7 min after onset of superfusion, the time required
for washout was variable.

In some tissues the e.j.p. amplitude re-

turned to its control amplitude within 5-10 min of resuming superfusion
with drug-free Krebs solution.

Usually, however, the effect of the

higher concentrations of DADL tested (1 and 3

~~)

did not completely

reverse, even after prolonged washing (20 min or more).

The Ec

50

for

the depression of e.j.p. amplitude by DADL was 500 pM (Figure 3).
3.26

Naloxone
Naloxone (up to 1

~M)

did not change the resting membrane poten-

tial of single smooth muscle cells, nor did it change the amplitude of
the e.j.p.

Naloxone (300 nM) reversed the depression of the e.j.p.

caused by superfusion with normorphine (300 nM).

Normorphine (300

ru~)

80
depressed the e.j.p. by an average of 32% (Figure 3).

Naloxone

(300 nM) reversed this depression, but the e.j.p. amplitude never
increased to more than its control value prior to administration of
normorphine (Figure 5).

In vasa acutely exposed to normorphine

(300 nM, for 10 min or less), naloxone increased e.j.p. amplitude by
64 + 11% (n

= 8). The largest effect observed was a doubling of the

e.j.p. in an experiment in which normorphine originally caused a
halving of its amplitude.
Naloxone was also tested on vasa that were maintained for 5-8 h
in Krebs solution containing normorphine (300 nH).

Cells from these

preparations responded to naloxone (300 nM) with an increase in e.j.p.
amplitude of 184 + 21% (n
3.27

= 4).

Contractions of the muscle
Short-duration increases in tension of the muscle ("twitches")

of the vas deferens occur in response to field stimulation of the
intramural nerves.

The height of the muscle twitches decreased if

normorphine (final bath concentration 100 nM - 1
the bath.

The normorphine Ec

50

~M)

was injected into

was 240 + 44 nM (n = 5).

81

Figure 5.

Reversal by naloxone of effect of normorphine on e.j.p.

The amplitude of the e.j.p. was depressed by approximately 50% after
5 min of

~xposure

to normorphine (300 nM).

This effect was subse-

quently reversed within 2 min of superfusion with naloxone (300 nM)
despite the continued presence of the normorphine.
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3.3
3.31

Effect of adenosine and cyclic nucleotides

Adenosine
Adenosine (300

~M

and 1 mM) depressed the amplitude of the evoked

e.j.p. without changing the resting membrane potential of the smooth
muscle cells.

This effect was rapid in onset and offset (2-5 min).

The magnitude of the effect of adenosine (1 mM) did not diminish if the
substance was repeatedly applied to the same cell at intervals of 10-15
min.

Adenosine (300

~M)

depressed the e.j.p. by 42

whereas adenosine (1 mM) depressed it by 64
3.32

±

±

3.3% (n

3.0% (n

= 11),

= 13).

Cyclic AMP and dbcAMP
The resting membrane potential of single smooth muscle cells was

not changed by the addition of cAMP or dbcAMP (up to 1 mM) to the
superfusing solution; both of these substances, however, depressed the
amplitude of the e.j.p.

The effect of the cyclic nucleotides, like

that of adenosine, was rapid in onset and offset (2-5 min).

The effect

did not diminish with repeated drug applications (at 10-15 min intervals) to the same cell or tissue, as illustrated for cAMP (1 mM) in
Figure 6.

Cyclic AMP (1 mM) decreased the e.j.p. amplitude by 52±

3.9% (n = 9).

The e.j.p. was decreased by 13% and by 30% in the two

cells on which cAMP (300
(two cells).
(n

~M)

was tested; cAMP (100

~M)

had no effect

DbcAMP (1 mM) decreased e.j.p. amplitude by 22.5 + 3.7%

= 8); lower concentrations of this substance were not tested.

84

Figure 6.
e.j.p.

Comparison of effect of cAMP with effect of normorphine on

During the first application (for 5 min) of cAMP (1 mM), the

e.j.p. was.

dep~ssed

by 57%.

The second application (also for 5 min)

of the same concentration of cAMP 10 min later resulted in a 61%
depression of the e.j.p. 'The amplitude of the e.j.p. was decreased by
66% after 7 min of superfusion with normorphine (1

~M).

normorphine was about 1,000 times more potent than cAMP.

In this cell,
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3.4
3.41

Effect of phosphodiesterase inhibitors

IBMX or SQ 20,006 alone
Neither the xanthine IBMX nor the non-xanthine SQ 20,006 (up to

1 mM) altered the resting membrane potential of smooth muscle cells,
but both increased the amplitude of the e.j.p.

This increase was slow

in onset, reaching its maximum after 8-12 min of drug superfusion, and
subsequently was slow to reverse upon washing (15-30 min).
(50

~M)

increased e.j.p. amplitude 58± 9% (n

increased it 167 ± 20% (n

=

7).

= 6)

IBMX

and IBMX (500

~M)

A second application of a given con-

centration of IBMX to the same cell or preparation (after 15 min - 3 h)
was less effective than the initial application (Table 3).
(500
3.42

~M)

enhanced e.j.p. amplitude by 54+ 13% (n

SQ 20,006

= 5).

The combination phosphodiesterase inhibitor and dbcAMP
DbcAMP alone weakly depressed the e.j.p., whereas IBMX increased

the e.j.p. (see above).

But IBMX and dbcAMP applied together were more

effective than IBMX alone in increasing the e.j.p. (Figure 7).
IBMX (50

~M)

in combination with dbcAMP (500

amplitude by 103 ± 16% (n

= 5). Also, IBMX (500

increased it by 182 ± 21% (n
dbcAMP (500

~M)

~M)

= 5).

Thus

increased e.j.p.
~M)

+

dbcAl~

The combination IBMX (500

increased it by an average of 285% (n = 3).

~M)

(250
~M)

+

These

effects on e.j.p. amplitude were larger in magnitude than those obtained by application of IBMX (50 or 500

~M)

alone (Table 3).

In one

experiment dbcAMP (1 mM), applied during superfusion with IBMX (50

~M)

87
Table 3.

Increase of e.j.p. amplitude by IBMX:

tration and repeated application.

effect of concen-

*Mean+ s.e. mean.

Numbers in

parentheses indicate the number of individual cells tested.

The effect

of IBMX (superfused for 10-15 min) on its second application was less
than that on its first application at both concentrations tested
(Student's t test; p<O.Ol).

Concentration
of IBMX
50 llM
500 llM

Increase of e .j .p.
amplitude (%) *
First application
58 +

9% (6)

167 + 20% (7)

Increase of e .j. P.
amplitude (%)*
Second application
12 +

6% (5)

82 + 10% (6)

88

Figure 7.

Comparison of effect of IBMX alone with effect of drug

combination IBMX + dbcAMP on e.j.p.

E.j.p. amplitude vs. time is

plotted as a histogram.· Each bin is the average of the amplitudes of
three consecutive e.j.ps.

The second application of IBMX (50

~M)

to

this tissue (for 6 min) resulted in a 32% increase of the e.j.p. (the
first application is not shown).
both IBMX (50

~M)

Subsequent exposure of the cell to

and dbcAMP (1 mM) for 6 min produced an increase in

e.j.p. amplitude of 95%.
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and after the effect of IBMX was maximal, increased e.j.p. amplitude by
59%.
The drug combination SQ 20,006 and dbcAMP was also more effective
than SQ 20,006 alone (Figure 8).

SQ 20,006 (500

increased e.j.p. amplitude by 392 + 43% (n

= 4);

~M)

+ dbcAMP (250

~M)

by itself, this con-

centration of SQ 20,006 had only a small effect (see above).
In a few experiments the effect of the drug combination IBMX and
dbcAMP was tested on the isotonic contractions of the smooth muscle of
the vas deferens.

The contraction produced by electrical stimulation

of the intramural nerves was reduced by superfusion with Krebs solution
containing IBMX (500

~M)

and dbcAMP (250

exogenous noradrenaline (10

~M)

~M).

Contractile responses to

and to high potassium solution (50 mM

KCl) could not be elicited in the presence of these two compounds.

91

Figure 8.

Comparison of effect of SQ 20,006 alone with effect of drug

combination SQ 20,006 + dbcAMP on e.j.p.
SQ 20,006

~500 ~M)

A 12 min exposure to

produced only a small increment in e.j.p. amplitude

(37%) in this cell.

Subsequent superfusion (also for 12 min) with the

same concentration of SQ 2b,006 in combination with dbcAMP (250 ~M)
resulted in a dramatic 336% enhancement of the amplitude of the e.j.p.
The effect of these substances in combination was not apparent until
at least 5 min after switching to the drug-containing solution (dead
time was about 1 min), and was also slow to reverse.

E.j.p. amplitude

returned to its control value only after 30 min of washing with drugfree Krebs solution.
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3.5

Effect of altered calcium ion concentration

Doubling the calcium ion concentration of the Krebs solution (to
5.08 mM) resulted in an increase in e.j.p. amplitude of 144 + 20%
(n

= 5),

whereas halving it (to 1.27 mM) resulted in a decrease in

e.j.p. amplitude of 66 + 4.9% (n

= 6).

These effects of altered

calcium ion concentration stabilized within 5-12 min of changing the
Krebs solution, and reversed within 10-15 min of resuming superfusion
with control Krebs solution (Figure 9).

When the calcium ion concen-

tration was doubled or halved, changes in the membrane potential of the
smooth muscle cells were less than 5 mV.

94

Figure 9.

Effect of doubling the calcium ion concentration on e.j.p.

The amplitude of the e.j.p. in this cell increased almost three-fold
(192%) durfng a 15 min superfusion with Krebs solution containing
twice the normal calcium ion concentration.

The effect of the changed

solution peaked after 10 ffiin and washed within 10-15 min.
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Effect of prolonged exposure to morphine in vivo

In order to assess the effect of prolonged exposure to morphine
on neuro-effector transmission in the mouse vas deferens, vasa from
mice that had received morphine injections for three d (see Methods)
were studied.

Vasa from these mice were compared to vasa from naive

mice which received no injections with respect to:

resting membrane

potential of smooth muscle cells, effects of normorphine, adenosine and
naloxone on the e.j.ps, and contractions of the muscle in response to
noradrenalin~.

3.61

Membrane potentials
The resting membrane potential of individual smooth muscle cells

was 63.0 + 2.1 mV (n

= 11)

in vasa from morphine-pretreated animals.

This value was not significantly different from the value of the
resting membrane potential in single cells of vasa from naive mice
(62.6

± 0.9

mV)(Student's t test).

Morphine pretreatment produced no

obvious change in the frequency and/or amplitudes of spontaneous
junction potentials, although careful measurements were not made.
3.62

Normorphine
Vasa from morphine-pretreated mice were maintained in Krebs solu-

tion containing normorphine (300 nM) (see Methods).
~M)

Normorphine (1-30

did not alter the resting membrane potentials of the smooth muscle

cells.

Normorphine (1

these vasa (Figure 10) .

~M)

did not depress the e.j .p. in cells from

Higher concentrations of normorphine (3-30

~M)

97

Figure 10.

Effect of normorphine (1

pretreated mouse).
containin~

~M)

on e.j.p. (morphine-

This tissue had been maintained in Krebs solution

normorphine.(300 nM) for 80 min at time zero; this concen-

tration of normorphine was also present throughout the recording
period.

Application of normorphine (1 ~M) for 6 min had no effect on

the amplitude of the e.j.p.
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decreased the amplitude of the e.j.p. (Figure 11) with a time course
similar to the time course of action in vasa from naive mice.

The

dose-response curve for depression of e.j.p. amplitude by normorphine
in vasa from morphine-pretreated mice was shifted to the right of the
dose-response curve for this action of normorphine in vasa from naive
mice (Figure 12).

The

Ec 50

for normorphine in vasa from morphine-

pretreated mice was 6.6

~M

mice).

values for tissues exposed to morphine in vivo

Individual EC

ranged from 3 to 30

50

~M,

(compared to 560 nM in vasa from naive

and did not overlap with individual EC 50 values

in vasa from naive mice (270- 890 nM).

Depressions of e.j.p. ampli-

tude by normorphine of 80-90% could be obtained in vasa from both
groups of animals.
3.63

Adenosine
Adenosine (300

~M

and 1 mM) decreased e.j.p. amplitude without an

effect on the resting membrane potential.

The effect had the same

rapid time course (onset and offset of action within 2-5 min) in
tissues from morphine-pretreated mice as in vasa from naive mice
(Figure 13).
(n

= 8).

Adenosine (300

~M)

depressed the e.j.p. by 40

Adenosine (1 mM) depressed the e.j.p. by 70

±

±

6.0%

4.4% (n

= 9).

The magnitude of these effects of adenosine in vasa from morphine-pretreated mice did not differ from the magnitude of the effects of adenosine in vasa from naive mice (Table 4).

100

Figure 11.

Effect of normorphine (3 and 10

pretreated mouse).

~M)

on e.j.p. (morphine-

This tissue had been maintained in Krebs solution

containin& normorphine ·(300 nM) for 2 h at time zero, and throughout
period of recording.

The e.j.p. amplitude was decreased by 20% by a

10-fold increase in the normorphine concentration of the Krebs solution (from 300 nM to 3

~M)

for 5 min.

reduced 50% by normorphine (10

~M),

In this tissue, the e.j.p. was

applied for 5.5 min.

these results with those illustrated in Figure 4.

Compare
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Figure 12.

Normorphine dose-response curves for depression of e.j.p.:

naive mice vs. morphine-pretreated mice.
pretreated mice were
phine (300 nM).

ma~ntained

Vasa from morphine-

in Krebs solution containing normor-

Bars represent+ s.e. mean.

Numbers in parentheses

indicate the number of individual cells tested at a given concentration.
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Figure 13.

Effect of adenosine on e.j.p. (morphine-pretreated mouse).

Adenosine (300

~M)

decreased the e.j.p. from 16 mV to 10.5 mV (a 34%

depression) whereas adenosine (1 mM) decreased it from 18 mV to 6 mV
(a 67% depression).

Both concentrations were applied for 5 min.

The

onset and offset of these 'effects in this cell were rapid (2 min), and
were typical of the time course of the effects of adenosine on cells
from both naive and morphine-pretreated tissues.
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Table 4.

Depression of e.j.p. by adenosine in vasa from naive and

morphine-pretreated mice.

*Mean+ s.e. mean.

Numbers in parentheses

indicate the number of cells tested at a given concentration.

There

was no difference between values in control (naive) mice and morphinepretreated mice at either concentration (Student's t test).

Percent inhibition of e.j.p.*
Adenosine (300 uM)

+ 3.0% (11)

Control (naive) mice

42

Morphine-pretreated mice

40 + 6.0%

(8)

Adenosine (1 mM)
64 + 3.3% (13)
70 + 4.4%

(9)
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3.64

Naloxone
Naloxone (up to 1

~M)

did not alter the resting membrane poten-

tial of the smooth muscle cells; nor did it cause any marked change in
the frequency of spontaneous e.j.ps when it was applied to the vasa
from morphine-pretreated mice.

In these vasa (maintained in Krebs

solution containing normorphine), changing to a solution that contained
both normorphine (300

ru~)

and naloxone (300 nM) caused a large increase

in the amplitude of the e.j.p. (Figure 14).

This effect was observed

in 9 cells from 9 different tissues; the average increase in e.j.p.
amplitude was 360 + 37% (range 254% to 600%).

The increase in e.j.p.

amplitude peaked within 3-5 min of the addition of naloxone to the
superfusing Krebs solution, but the effect was slow to reverse (Figure
14).

In most instances the impalement was terminated before the e.j.p.

amplitude returned to its pre-naloxone value.
3.65

Drug-free Krebs solution
The superfusion of vasa from morphine-pretreated mice (maintained

in Krebs solution containing normorphine) with normorphine-free Krebs
solution caused an increase in the amplitude of the e.j.p.

In the

three cells from three different tissues that were tested in this
manner, application of drug-free Krebs solution (for 8-11 min)
increased e.j.p. amplitude by 365%, 240% and 100% respectively.

108

Figure 14.

Effect of naloxone on e.j.p. (morphine-pretreated mouse).

Normorphine

(~00

for 4 h

nM) was present throughout the recording period and

p~eviodsly

at time zero.

The addition of naloxone (300 nM)

to the superfusing Krebs solution (for 5 min) caused a 7-fold (600%)
<

increase in the e.j.p.
out the naloxone.

This effect was slow to reverse upon washing

A second application of naloxone (300 nM) to the

cell was again effective in enhancing the e.j.p. amplitude, although
the recording was prematurely terminated before the magnitude and
duration of this second effect could be ascertained.

-.,.

~

....J

~I
z

<l:

-

..,.
0

(A UJ)

"dT.3

"'1"

l{')

"'1"

0

(")

1.()

-

w
~L
I-

109

110
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Contractions of the muscle
The contractions of the smooth muscle of the vas deferens in

response to exogenous noradrenaline were measured for tissues prepared
from both naive and morphine-pretreated mice.

When noradrenaline (1

~M

- 10 mM) was added to the organ bath, the vas deferens developed an increase in tension which peaked rapidly and then declined before washout
of the drug,

The rate of change of tension increased with increasing

drug concentration, provided the tip of the injecting needle was in the
same position in the organ bath relative to the tissue.
centrations of noradrenaline (100

~M-

With high con-

10 mM), the initial peak tension

was followed by a series of rapid fluctuations in tension of lower
amplitude.

Only the initial peak response was measured.

Dose-response

curves for these responses of the vasa to noradrenaline were constructed for vasa from both morphine-pretreated and naive mice (Figure
15).

The noradrenaline

Ec 50

(concentration producing a peak tension

which was one-half of the maximum response to this substance) was 10.4
~M

in vasa from morphine-pretreated mice and 10.5

mice.

~M

in vasa from naive

The maximum response of the tissue to noradrenaline (expressed

as mg tension/10 mg wet weight of tissue) was 2,044

± 106

vasa exposed to morphine in vivo and 1,851 + 109 (n

= 13) in vasa from

naive mice.
test).

± 0.6

(n

= 8) in

These values were not significantly different (Student's t

The wet weight of the vasa from morphine-pretreated mice (11.5
mg, n

= 8)

also was not different (Student's t test) from the wet

weight of vasa from naive mice (12.7

± 0.5

mg, n

= 14).

111

Figure 15.

Dose-response curves for contractile responses of the

smooth muscle to noradrenaline:
morphine-p~etreated

mice.

vasa from naive mice vs. vasa from

Bars indicate+ s.e. mean.

Numbers in

parentheses indicate the number of tissues tested with a given concentration.

At all concentrations, differences between values from

control animals and values from morphine-pretreated animals were compared using Student's t test.

Only at one concentration of noradren-

aline (1 mM) were these values significantly different (p

= 0.04).
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The nerve-mediated muscle twitches of vasa from morphine-pretreated mice were inhibited by normorphine (1-30

Ec 50

Individual

values for normorphine were determined for six vasa from morphine-

pretreated mice and ranged from 1.6
was 4,000

Ec 50

~M).

±

890 nM (n

~M

to 7.8

~M.

The normorphine

Ec 50

= 6), which was significantly different from the

for the inhibition by normorphine of the muscle twitches in vasa

from naive mice (240 + 44 nM).
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Effect of cyclic nucleotides and IBMX on the actions of
normorphine and opioid peptides

3.71

Normorphine
The effect of normorphine on e.j.p. amplitude was measured in

vasa superfused with cAMP (1 mM) and compared to its effect in vasa
that were not treated with this substance.

This concentration of cAMP

depressed e.j.p. amplitude by 52± 3.9% (see above).
superfused

w~th c&~

(1

w~)

The tissue was

for 5-30 min before testing normorphine.

Stimulus voltage was adjusted prior to the application of cAMP so that
the e.j.p. was between 10 and 25 mV in amplitude before the application
of normorphine.

Normorphine decreased e.j.p. amplitude in the presence

of cAMP (1 mM), with a time course of onset and offset of action
similar to its effect in the absence of this nucleotide in other vasa.
The Ec

50

for depression of e.j.p. amplitude by normorphine in the

presence of cAMP (1 mM) was 700 nM, as determined from the composite
dose-response curve (Figure 16).

For comparison, the dose-response

curve for normorphine in vasa not treated with cyclic nucleotide is
also illustrated in this figure.
Normorphine was also tested in preparations that had been superfused with both IBMX (50

~M)

and

dbc&~

(500

~M)

for at least 12 min.

This drug combination increased e.j.p. amplitude by 103 + 16%, as
determined by testing on other tissues (see above).

Normorphine still

decreased e.j.p. amplitude in the presence of these substances and the
time course of onset of its effect was not changed.

Often the reversal
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Figure 16.

Normorphine dose-response curves for depression of e.j.p.:

effect of cAMP. and the drug combination IBMX +

dbck~.

.

Dose-response

curves for•normorphine were constructed using results from tissues
that were not pretreated with any drugs, results from tissues exposed
to cAMP (1 mM) and results from tissues pretreated with IBMX (50
+ dbcAMP (500

~M).

Bars represent+ s.e. mean.

~M)

The number of indi-

vidual cells tested at each concentration was at least six.

Control

values and values after incubation in cAMP or incubation in the drug
combination IBMX + dbcAMP were compared by one-way analysis of
variance at three concentrations (300 nM, 1

~M

and 3

~M).

No signi-

ficant effect of these substances on the response to normorphine was
found.
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of the depression of the e.j.p. caused by normorphine was faster in
vasa superfused with IBMX + dbcAMP (Figure 17) than in vasa not treated
with these substances.

The dose-response curve for normorphine in

tissues superfused with both IBMX (50

~M)

and dbcAMP (500

~M)

was vir-

tually superimposable on the dose-response curve obtained from tissues
not exposed to these substances (Figure 16).

+ dbcAMP (500

~M)

590 nM for tissues exposed to IBMX (50

The normorphine EC
~M),

50

was

as com-

pared to 560 nM in drug-naive preparations.
3.72

DAEA
The effect of DAEA on e.j.p. amplitude was tested on vasa exposed

to both IBMX (500

~M)

and

dbc&~

(250

~M)

for 12 min or more, and com-

pared to the effect of DAEA on vasa not so treated.

In other experi-

ments, IBMX and dbcAMP applied together in these concentrations
increased e.j.p. amplitude by 182

± 21%

(see above).

DAEA (10-300 nM)

still decreased e.j.p. amplitude in the presence of IBMX + dbcAMP
(Figure 18) ; the time course of this effect was the same as in untreated tissues.

The potency of DAEA was slightly enhanced in tissues

exposed to IBMX + dbcAMP compared to control tissues, as is evident
from the composite dose-response curves (Figure 19).

The magnitude of

the effect of DAEA in tissues exposed to IBMX + dbcAMP was signifi. cantly different from the magnitude of the effect in control tissues at
two concentrations (10 nM:
The EC

50

p<O.Ol; 100 nM:

p<O.OS; Student's t test).

for DAEA in vasa superfused with IBMX +

dbc.~

was 27 nM,
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Figure 17.

Effect of normorphine (1

presence of IBMX (50

~M)

~M)

+ dbcAMP (250

on e.j.p. in absence and

~M):

same cell.

During the

time perio@ indicated by the striped bar and dotted line, stimulus
voltage was adjusted (from 23 to 16 volts) to offset the increase of
the e.j.p. caused by IBMX + dbcAMP.

Normorphine (1

~M)

depressed

e.j.p. amplitude by 55% in the control solution and by 52% after 12
miri of superfusion with the combination of IBMX

+ dbcAMP.

The effect

of normorphine washed out faster during exposure to IBMX + dbcAMP.
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Figure 18.
dbcAMP.

Effect of DAEA on e.j.p. during superfusion with IBMX +

This tissue was exposed to IBMX (500

~M)

and

dbc&~

(250

~M)

throughout. the 'period of recording, as well as for 12 min previous to
time zero.

DAEA (10-300 nM) decreased the e.j.p. amplitude in this
'

cell, and the magnitude of the effect was larger for the higher concentrations.
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Figure 19.

Dose-response curves for depression of e.j.p. by DAEA:

effect of IBMX + dbcAMP.

.

These dose-response curves were constructed

using results from tissues not exposed to any drugs and results from
tissues superfused with the drug combination IBMX (500
(250

~M).

Bars

represent~

s.e. mean.

~M)

and dbcAMP

Numbers in parentheses indi-

cate the number of individual cells tested at a given concentration.
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whereas the EC
3.73

50

for DAEA in control vasa was 50 nM.

DADL
The effect of DADL on e.j.p. amplitude was tested on vasa super-

fused with both IBMX (500

~M)

and dbcAMP (250

~M)

for 12 min or more,

and compared to the effect of DADL on control tissues.

This combina-

tion of IBMX + dbcAMP increased the e.j.p. amplitude (see above).

DADL

(300 pM- 3 nM) decreased the amplitude of the e.j.p. in the presence
of IBMX +

db~AMP

(Figure 20) ; the time course of this effect was the

same as in untreated tissues.

Composite dose-response curves for DADL

in tissues superfused with IBMX +
illustrated in Figure 21.

dbcAl~

and in control tissues are

There were no significant differences

between values from these two groups of vasa (Student's t test).
Ec

50

for DADL in the treated vasa was 540 pM and the Ec

vasa was 500 pM.

50

The

in control
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Figure 20.
dbcAMP.

Effect of DADL on e.j.p. during superfusion with IBMX +

This.tissue was exposed to IBMX (500

~M)

+ dbcAMP (250

~M)

throughout.the period of recording, as well as for 12 min previous to
time zero.

In this cell, DADL (300 pM) depressed the e.j.p. by 30%,

DADL (1 nM) depressed it by 61% and DADL (3 nM) depressed it by 83%.
It can be seen that the effects of the higher concentrations of the
peptide tested (1 and 3 nM) did not completely reverse upon returning
to superfusion with normal Krebs solution.
of the depressant action of this compound.

This was characteristic
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Figure 21.

Dose-response curves for depression of e.j.p. by DADL:

effect of IBMX + dbcAMP.

These dose-response curves were constructed

using resu~ts from tissues not exposed to any drugs, and results from
tissues superfused with the drug combination IBMX (500
(250

~M).

'

Bars represent± s.e mean.

~M)

and

dbck~

Numbers in parentheses indicate

the number of individual cells tested at a given concentration.
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3.8

Effect of altered calcium ion concentration on the action of
normorphine

3.81

Stimulus strength adjusted
The effect of normorphine on e.j.p. amplitude was determined in

tissues maintained in twice the normal calcium ion concentration (5.08

mM) for 1-6 h.
e.j.p. by 144

Doubling the calcium ion concentration increased the

± 20%

in other experiments (see above).

The stimulus

voltage was adjusted so that e.j.ps were between 10 and 25 mV in amplitude before testing normorphine; it is presumed that this adjustment
has compensated for the effect of high calcium on the e.j.p.

Normor-

phine decreased e.j.p. amplitude in tissues maintained in high calcium
solution (Figure 22) and the time course of the effect was not different from its time course in normal calcium solutions.
The effect of normorphine on e.j.p. amplitude was also measured
in vasa maintained in one-half the normal calcium ion concentration
(1.27 mM) for 1-6 h.

Halving the calcium ion concentration decreased

the e.j.p. amplitude by 66 + 4.9% in other experiments (see above).
Normorphine was tested on e.j.ps 10-25 mV in amplitude; it is presumed
that the stimulus voltage has been adjusted to compensate for the
effect of low calcium.

Normorphine depressed the e.j.p. in tissues

maintained in low calcium solution (Figure 23).
The dose-response curves for the effect of normorphine on e.j.p.
amplitude in tissues maintained in high calcium (5.08 mM), normal
calcium (2.54 mM) and low calcium (1.27 mM) solutions are illustrated
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Figure 22.
high calcium

Effect of normorphine on e.j.p. during superfusion with
~olution.

The tissue was superfused with Krebs solution

containing.calcium (5.0S mM) throughout the recording, and for 4.5 h
previously.

The action of normorphine was related to the concentra-

tion applied, and in this cell the following depressions of e.j.p.
amplitude occurred:

normorphine (100 nM), 26%; normorphine (300 nM),

55%; and normorphine (1

~M),

79%.
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Figure 23.

Effect of normorphine on e.j.p. during superfusion with

low calcium sqlution.

This tissue had been bathed in Krebs solution

containing.calcium (1.27 mM) for 3 h previous to time zero.

Four

concentrations of normorphine were tested on the e.j.p. in this cell,
which was particularly sensitive to its action.
(30 nM) had no effect, normorphine (100

~M)

Although normorphine

depressed the e.j.p. by

34%, normorphine (300

ru~)

depressed it by 83%.

The impalement ended before the effect of the

final

applicatio~

depressed it by 62% and normorphine (1

of normorphine had completely washed out.

~M)
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in Figure 24.

Values obtained in high, normal or low calcium solutions

were compared at four concentrations of normorphine (100 nM, 300 nM,
1

~M

and 3

~M)

using one-way analysis of variance.

There was a signi-

ficant relationship between the effectiveness of normorphine and the
calcium ion concentration at only one of these concentrations (300 nM:
p

= 0.02).

This was due to a difference between the effectiveness of

this concentration of normorphine in control vs. low calcium solution
(Figure 24).

The EC

50

for normorphine was 270 nM in low calcium

solution (1.27 mM), 370 nM in normal calcium solution (2.54 mM) and
410 nM in high calcium solution (5.08 mM) as estimated from the
composite dose-response curves (Figure 24).
3.82

Stimulus strength not adjusted
~M)

in both normal and low calcium

solutions was tested on the same cell.

The stimulus strength was not

The effect of normorphine (1

changed when the calcium ion concentration was changed (Figure 25).
Normorphine (1

~M)

depressed the e.j.p. by 74

±

3.1% in normal calcium

and by 75 + 4.8% in low calcium, in the five cells on which it was
tested in this manner (Table 5).
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Figure 24.

Normorphine dose-response curves for depression of e.j.p.

in tissues maintained in different calcium ion concentrations.

These

dose-response curves were constructed using results from vasa maintained in Krebs solutions containing high (5.08 mM), normal (2.54 mM)
or low (1.27 mM) calcium ion concentrations.
mean.

Results from 52 cells (23 tissues).

Bars represent + s.e.
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Figure 25.
sion of
meters.

Effect of halving the calcium ion concentration on depres-

e.j.p~

by normorphine:

same cell and same stimulation para-

COntinuous record of e.j.p. amplitude during the impalement

of a single cell.
recording.

Stimulation strength was constant throughout the

During the time interval indicated by the open bar, the

calcium ion concentration of the superfusing solution was reduced from
2.54 mM to 1.27 mM.

In this cell, normorphine (1

~M)

decreased e.j.p.

amplitude by 84% in normal calcium solution and by 64% in the solution
with reduced

calc~um

concentration.
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Table 5.

Effect of normorphine (1

calcium:

same cell.

~M)

Normorphine (1

on e.j.p. in normal and low

~)

was tested on five cells

bathed first in solutions with normal calcium (2.54
solutions with low calcium (1.27 mM).
constant.

ru~),

then in

Stimulation parameters were

There was no difference between the mean depression of the

e.j.p. by normorphine (1

~)

in normal and low calcium (Student's t

test).

Calcium (2.54 mM)

Calcium (1.27 mM)

Cell II

E.j •P. amp.
(mV)

Depression of
e.j .p. (%)

E.j .p. amp.
(mV)

Depression of
e.j .p. (%)

7259-3

25

74

14

85

8019-5

22

68

8

67

8149-5

29

85

6

64

10169-4

44

68

12

71

10179-1

36

77

10

88

X+ s.e.m.

31 + 4.0 mV

74 + 3.1%

10 + 1.4 mV

75 + 4.8%

4.
4.1

DISCUSSION

E.j.p. amplitude as a measure of transmitter release

Increasing the strength of stimulation of the intramural nerves
of the mouse vas deferens will increase the number of nerve fibers that
are activated and hence increase the amount of transmitter released
into the junctional clefts in the vicinity of a single smooth muscle
cell.

The amplitude of the e.j.p. increases with strength of stimula-

tion, and hence it can be concluded that e.j.p. amplitude is a quantitative estimate of transmitter release.

Other aspects of e.j.p.

configuration also vary with stimulus strength, such as the rate of
rise of the e.j.p. (in V/s) and the area under the depolarization
curve.

Why was peak amplitude measured in the present experiments, and

not these latter characteristics?
The rate of rise of the e.j.p. increases with stimulus strength,
and hence with the quantity of transmitter that interacts with the
postsynaptic membrane.
and more accurate.

But measurements of peak amplitude are easier

Small errors in measurements of amplitude as a

function of time would produce large changes in the calculated rate of
rise, whereas measurements of e.j.p. amplitude in the present study
were accurate within+ 0.5 mV.

Furthermore, the rate of rise of the

e.j.p. in a particular cell which has been produced by a fixed amount
of transmitter is dependent on the distribution of transmitter release
sites in the vicinity.

Release directly onto the impaled cell would
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14]
result in a fast rate of rise whereas release onto neighboring or more
distant cells would result in a decreased depolarization rate.
The area under the depolarization is influenced by the rise time,
peak amplitude and decay time of the e.j.p.

The ionic currents, and

hence the conductance changes which produce the e.j.p., have not yet
been measured; therefore the duration of transmitter action is not
known.

In the few smooth muscle cells of the mouse vas deferens in

which conductance increases are observed in connection with transmitter
action, these increases occur during the early portion of the e.j.p.
(Holman, 1970).

Thus the duration of the e.j.p. most likely does not

reflect continued action of transmitter on the smooth muscle membrane.
The falling phase of the e.j.p. probably is determined by the passive
electrical properties of the smooth muscle membrane, as postulated by
Bywater & Taylor (1980).

They found that the time constant of decay of

the evoked e.j.p. in the guinea-pig vas deferens was closely similar to
the time constant of the smooth muscle membrane in this tissue.

Since

the final configuration of the e.j.p. is dependent on postsynaptic
membrane properties as well as presynaptic events (transmitter release),
the area under.the depolarization curve was not used as a quantitative
measure of transmitter release.

An increase in the amplitude of the e.j.p. results from the
action of increasing quantities of transmitter.

The transmitter pro-

duces the potential change by increasing the ionic conductance of the
smooth muscle membrane, but the potential change is not linearly related to the conductance change (Martin, 1955).

This non-linear

relationship occurs because as the membrane becomes depolarized and
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its potential approaches the equilibrium potential of the transmitter,
the ionic driving force becomes less.

Thus, at the height of the

e.j .p., a given quantity of transmitter will produce a smaller potential change than would the same amount of transmitter applied to a
resting membrane.

To account for the non-linear relationship between

transmitter action (conductance change) and e.j.p. amplitude (potential
change), the following correction factor may be applied (Martin, 1955):

v'

= v (1 - ~)-l
v0

where v' =corrected e.j .p., v =measured e.j.p. amplitude, and
V = VE- Vm (VE =equilibrium potential for e.j.p. and Vm =resting
0

membrane potential).

The corrected value of the e.j.p. (v') would be

an estimate of "transmitter release" and hence would have no units.
Any estimate produced by this method would be inaccurate because the
noradrenaline equilibrium potential (VE) is not known (see Introduction, p. 48-49).

Also, the actual value of the resting membrane

potential (V ) is difficult to measure accurately because microelectrode
m

impalement of cells probably results in some degree of damage.

If,

however, an equ;librium potential of 0 mV and a resting membrane potential of -62 mV (see Results, p. 65) are assumed, then e.j.p. amplitudes
can be corrected for non-linear summation as shown in Table 6.

It is

obvious that the greater the amplitude of the e.j.p., the less accurately does the potential change of the membrane reflect the quantity of
transmitter released in the vicinity of that membrane.

In most of the

present experiments, the effectiveness of opiate agonists was tested on
e.j .ps of approximately the same amplitude.

In a few experiments, such
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Table 6.
summation.

Correction of e.j.p. amplitude to account for non-linear

*v' = v (1 -

v -1
v)

(see text).

Assumptions:

0

vm =

-62 mV; VE = 0 mV,

E .j .p. amplitude
(mV) Recorded

Corrected e .j. p.
"Transmitter release"

5

5

10

12

15

20

20

30

25

42

30

58

35

80

40

114

45

167

50

250
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as effect of stimulus strength on potency of normorphine and in some
low calcium experiments, the effect of normorphine is assessed on
e.j.ps of different amplitudes.

The implications of non-linear summa-

tion will be discussed in relation to the results of these studies.
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4.2

Depression of e.j .p. by opiates and opioid peptides

Normorphine decreased the amplitude of the evoked

~.j.p.

in the

isolated vas deferens of the mouse, an action that was reversed by
naloxone.
The EC

50

This confirms the observations of Henderson & North (1976).
for normorphine in the present study (560 nM) was similar to

the value obtained by those authors (430 nM), despite the fact that
different strains of mice were used in the two studies.

The effect of

normorphine on the e.j.p. is likely to be the result of a decrease in
the amount o7 transmitter released from the adrenergic varicosities in
response to nerve stimulation (see Introduction).
DAEA is an enkephalin analog that is resistant to enzymatic
destruction (Pert, Bowie, Fong & Chang, 1976) and it acts primarily on
~

receptors (Shaw, Turnbull, Dutta, Gormley, Hayward & Stacey, 1978).

It also depressed the e.j.p., and was more potent in this action than
normorphine, with an EC

50

of 50 nM.

Such an effect on the e.j.p. of an

5
opioid peptide had previously been demonstrated for Met -enkephalin
(Waterfield et al., 1977).
A second enkephalin analog, DADL,

~as

also tested on the e.j.p.

This opioid peptide is a potent and specific agonist at the 8 receptor
(Chang & Cuatrecasas, 1979).

Neuro-effector transmission in the mouse

vas deferens was extremely sensitive to the depressant action of this
peptide; the Ec
500 pM.

50

for the depression of e.j.p. amplitude by DADL was

DADL was thus about 1,000 times more potent in this action

than normorphine, a result which is consistent with the preponderance
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of a-type opiate receptors in the mouse vas deferens
1977).

(Lord~

al.,

It is assumed that the decrease in e.j.p. amplitude in the

presence of the opioid peptides results from a depression of transmitter release by these substances, as is true for normorphine
(Henderson & North, 1976).
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4.3

Effect of control e.j.p. amplitude and stimulus strength on the
potency of normorphine
The calculated percentage inhibition of e.j.p. amplitude by nor-

morphine was not related to the control amplitude of the e.j.p., because normorphine was as effective on e.j.ps of initially large amplitude (35 mV) as on e.j.ps of initially smaller amplitude (10 mV)
(Table 1).

Any change in the effectiveness of normorphine (1

~M)

as a

function of e.j.p. amplitude may not be evident because this concentration falls an the less sensitive (lower slope) portion of the doseresponse curve (Figure 3).

This caveat does not apply for the lower

concentrations of normorphine (especially 300 nM), although the
effectiveness of these lower concentrations on e.j.p. amplitude is more
variable from cell to cell (note standard deviations in Figure 3).

In

a few experiments, normorphine (100 nM or 300 nM) was tested on a
large amplitude e.j.p. and a small amplitude e.j.p. of the same cell.
Depending on the cell, normorphine was more effective, equally effective
or less effective on the larger amplitude e.j.p. as compared to the
smaller amplitude e.j.p.
More nerve fibers must be excited in order to elicit an e.j.p.
of larger amplitude (35 mV vs. 10 mV).

The present results indicate

that, at least for the nerve fibers with thresholds for excitation in
a limited range of stimulus strengths, the sensitivity to normorphine
must be similar.

In all experiments the stimulus strength used to

evoke an e.j.p. was submaximal; in most cells even the large amplitude
(30-40 mV) e.j .ps did not give rise to action potentials.

If the
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potency of normorphine were measured on e.j.ps elicited by supramaximal
stimulation, which usually are accompanied by action potentials and
muscle contractions, and compared to its potency on submaximal e.j.ps,
differences might very well have been found.

Hughes et al. (1975a)

measured the effect of normorphine on the nerve-evoked muscle contractions of the mouse vas deferens.

They observed that normorphine was

more effective on vasa stimulated with submaximal current strengths
(Ec

50

= 120

nM) compared to its efficacy on vasa stimulated with just

supramaximal stimuli (Ec

50

= 440 nM).

Submaximal vs. supramaximal

e.j.ps were not compared in the present study because only submaximal
stimulation strengths were used in all experiments.
If the amplitude of the e.j.p. is corrected using Martin's nonlinear summation formula so that the e.j.p. reflects "transmitter
release" (Table 6), then the effectiveness of normorphine is apparently
greater for large amplitude e.j.ps.

For example, normorphine (300 nM)

decreases the amplitude of 35 mV e.j.ps by an average of 39%, and
decreases the amplitude of 10-11 mV e.j.ps by 46% (Table 1).

The

percentage depression of the "transmitter release" than these e.j.ps
represent is 60% for high release and 48% for low release.

The calcu-

lations were also made for e.j.ps depressed by normorphine (100 nM and
1

~M),

and the results are similar.

One possible explanation for the

apparent greater effectiveness of normorphine on high levels of transmitter release may be related to the geometry of release in the vas
deferens.

For large amplitude e.j.ps, more nerve fibers close to the

impaled cell are likely to be excited, because the stimulus strength
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has increased.

An inhibitory effect of normorphine on transmitter

release in the vicinity of a given cell would be more likely to result
in a measurable decrease in e.j.p. amplitude than would inhibition of
transmitter release at more distant sites.

Transmitter that is re-

leased directly onto or near a cell makes a larger contribution to the
amplitude of the e.j.p. than does transmitter released onto distant
cells.
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4.4

Prolonged exposure to morphine in vivo

Intracellular recordings were made from smooth muscle cells of
vasa taken either from naive mice or from mice pretreated with morphine.

The effects of opiates on neurotransmission in these vasa were

compared.
follows.

The three main questions addressed by this study were as
Does chronic morphine pretreatment lead to changes in the

resting properties of the smooth muscle cells of the mouse vas
deferens?

Does tolerance develop to the inhibitory action of morphine

at this neuio-effector junction?

Can the administration of naloxone

in vitro to a vas deferens exposed to morphine in vivo lead to changes
in neuro-effector transmission which are an indication of "dependence"?
These aspects will be discussed in turn.

4.41

Resting membrane properties of the smooth muscle cells
Opiates depress transmitter release in the mouse vas deferens

in vitro (see above).

Prolonged exposure to high concentrations of

morphine in vivo may effectively interrupt neuro-effector transmission
in the vas deferens so as to produce a pharmacological denervation.

If

excitable cells are chronically deprived of their normal physiological
stimuli they become more sensitive to excitatory substances.

This

phenomenon in smooth muscle is postjunctional supersensitivity
(Fleming, Urquilla, Taylor & Westfall, 1975).

In the guinea-pig vas

deferens, postjunctional supersensitivity produced by surgical denervation is accompanied by a depolarization of the smooth muscle cells
(Fleming & Westfall, 1975;

Fleming~

al., 1975).

Morphine pretreat-
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ment of mice did not alter the resting membrane potentials of single
smooth muscle cells of their vasa deferentia.

Presumably, during

chronic exposure to morphine in vivo, neuro-effector transmission is
more or less restored to normal due to the development of tolerance to
the initial depressant effect of morphine on transmitter release (see
below).

Under these conditions, postjunctional supersensitivity would

not develop.

Another possibility is that postjunctional supersensi-

tivity in the mouse vas deferens is not accompanied by a change in the
resting membrane potential of the smooth muscle cells.

This is true

for the smooth muscle cells of the supersensitive rat vas deferens
(Goto, Westfall & Fleming, 1978).

This is not likely because an in-

creased sensitivity to transmitter did not develop in vasa from
morphine-pretreated mice (see below).
Most of the experimental evidence suggests that noradrenaline is
the transmitter released from the sympathetic nerve varicosities in the
mouse vas deferens, and that the noradrenaline so released mediates the
contractile response of the muscle to stimulation of the intramural
nerves (see Introduction).

Because surgical denervation leads to

supersensitivity of smooth muscle to noradrenaline.and other substances
(see Fleming et al., 1975), the effect of chronic morphine treatment on
the response of the smooth muscle cells of the mouse vas deferens to
exogenous noradrenaline was examined.

There was no change in the sen-

sitivity of the muscle cells to noradrenaline after chronic morphine
treatment.

Rae, Neto & de Moraes (1977) reported that long-term treat-

ment of mice with morphine does lead to a supersensitivity of their
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vasa deferentia to noradrenaline.

The differences between the results

of these investigators and the results of the present experiments may
be related to differences in the schedule of morphine administration.
Rae et al. administered morphine for 10 days, whereas mice were treated

--

for 3 days in the present study.

Perhaps any changes in muscle sensi-

tivity related to prolonged morphine treatment have not developed
within 3 days (see below).

Also, injection of animals twice a day

(Rae et al.) as compared to 3 times a day (present study) may result in
longer periods of relative withdrawal from morphine.

Supersensitivity

is a common finding in withdrawal from morphine both in vivo (Pollock,
Muir, MacDonald & Henderson, 1972) and in vitro (North & Karras, 1978a).
The noradrenaline EC

50

for producing a contractile response of

the vas deferens in vitro was not different in vasa from mice administered morphine for 3 days as compared to vasa from naive mice.

There

was, however, a tendency for vasa from morphine-pretreated mice to
respond to the higher concentrations of noradrenaline with larger
increases in tension (Figure 15).

A supersensitivity of smooth muscle

which is characterized by an increased maximum response to an agonist,
without an associated leftward shift of the dose-response curve to that
agonist, has been observed under conditions in which blood corticosteroid levels are elevated.

Such conditions include:

morphine with-

drawal, thyroidectomy, injection of a single dose of reserpine, or
chronic administration of corticosterone (Gibson & Pollock, 1975).

The

stress of daily multiple injections of a drug could also result in
elevated levels of plasma glucocorticoids.

Perhaps administration of

morphine to mice for a longer time in the present experiments would
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have resulted in a statistically significant increase in the maximum
response of the vas deferens to noradrenaline, an increase which may be
only partially developed after three days.
Most importantly, significant tolerance to the effect of opiates
on transmitter release (see below) can be demonstrated in vasa which
are not supersensitive, or have only a marginally increased sensitivity,
to the transmitter noradrenaline.

Thus supersensitivity of the post-

synaptic effector cell to transmitter does not account for tolerance to
morphine in this tissue.
4.42

Tolerance to the effect of normorphine
The EC

50

for the depression by normorphine of e.j.ps was twelve

times higher in vasa from morphine-pretreated mice than the Ec
vasa from naive mice (Figure 12).

in

50

Transmitter release in vasa from

morphine-pretreated mice was thus relatively insensitive to normorphine.

The isolated tissue may, therefore, be said to be tolerant to

the inhibitory action of normorphine on the nerve terminals.

Cox

(1978) reported a four-fold degree of tolerance to the inhibitory
action of morphine on the nerve-mediated contractions of vasa.

These

vasa were removed from mice which had been implanted with morphine
pellets for five days.

A previous study of the effect of opiates on

the contractions of vasa from pellet-implanted mice (Waterfield, Hughes

& Kosterlitz, 1976) also did not report the high degree of tolerance
seen in the present study.

The experimental procedures of these

studies and the present one differ in two major respects.
(1978) and

Waterfield~

First, Cox

al. (1976) used pellet implantation, whereas
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multiple injections (8 hour intervals) was the method of morphine pretreatment in the present study.

Second, in the other studies the con-

tractions of the smooth muscle in response to supramaximal stimulation
of the nerves were measured.

In the present study the effectiveness of

normorphine was assessed on the amplitude of the e.j.p.; the e.j.p. was
elicited by submaximal stimulation of the intramural nerves.
The pattern of exposure of the vas deferens to morphine would
differ in pellet-implanted mice as opposed to mice receiving multiple
injections.

Vasa in pellet-implanted mice would be exposed to lower

but less variable concentrations of morphine.

In contrast, blood

levels of morphine would markedly vary in the mice receiving intraperitoneal injections.

The plasma concentration of morphine was mea-

sured in mice that were treated with the same morphine injection
schedule as the animals whose vasa were used for intracellular recordings.

Two hours after the last (ninth) morphine injection of 140 mg/kg

(the time when the mouse would have been killed and the vasa removed
for experimentation), the plasma morphine concentration averaged 6.7
(range 3.2 to 13.8

~M;

= 4).

n

~M

Eight hours after the final injection

(the time for the next injection, if the treatment schedule would have
continued), the morphine concentration in the plasma averaged 900 nM
(range 250 nM- 1.5
Normorphine (1

~M)

~M;

n

= 6)

(Wainer, personal communication).

did not depress the e.j.p. in vasa of morphine-

pretreated mice (Figure 10).

Thus with this injection schedule, neuro-

effector transmission would be periodically restored to normal (when
the blood level approached 900 nM) and would be intermittently depressed
(when the blood level approached 7

~M).

This assumes that the concen-
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tration of morphine in the vicinity of the opiate receptors in the vas
deferens is similar to the plasma concentration.

This schedule of

exposure to morphine may be more favorable for the development of
tolerance in the mouse vas deferens, as opposed to a schedule of
exposure which results in steadily declining blood concentrations (such
as pellet implantation).
When the effect of morphine is studied on the contractions of
the smooth muscle of the vas deferens, supramaximal stimulation of the
intramural nerves is used to elicit these contractions.

But the po-

tency of normorphine in inhibiting the muscle contractions is greater
if submaximal stimulation currents are used (Hughes et al., 1975a).
E.j .ps were elicited by submaximal stimulation strengths, but the
effect of normorphine on the e.j.p. was independent of the e.j.p.
amplitude, and of the stimulus strength used to evoke it (Table 1).
Furthermore, in the present study the potency of normorphine on
muscle contractions evoked by supramaximal stimulus strengths was compared to its potency in inhibiting the amplitude of e.j.ps elicited by
submaximal stimuli, in different mice of the same strain.

In vasa from

naive mice of .the CF-1 strain, normorphine was as effective or more
effective in inhibiting the contractile responses of the muscle (EC 50
values 165-400 nM) in the vasa tested in this manner, as it was in
depressing the e.j.p. (Ec

50

values 270-890 nM) in other vasa.

A

similar relationship held for vasa from morphine-pretreated mice.
these tissues, the Ec

50

In

values for normorphine for inhibition of the

nerve-evoked muscle contraction (1.6-7.8

~M)

were similar to the values
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for the inhibition of the e.j .p. (3-30

~M).

For these reasons, it is

unlikely that the high degree of tolerance (twelve-fold) observed in
the present study as opposed to previous studies is related to the
method used for assessing the potency of opiates (e.j.p. amplitude) or
to the use of submaximal stimulation strengths to elicit transmitter
release.
Is it possible that the shift to the right of the dose-response
curve for the effect of normorphine on the e.j .p. in vasa from morphine-pretreated mice was a consequence not of in vivo exposure to
morphine, but of in vitro exposure to normorphine (300 nM)?

To inves-

tigate this possibility, some vasa from naive mice were maintained in
Krebs solution containing normorphine (300 nM) for 1-5 hours, and the
effect of higher concentrations of normorphine (1 and 3
tested.

Normorphine (1 and 3

in these vasa normorphine (1

~M)

~M)

~M)

were

still depressed the e.j.p.

Although

was significantly less effective than

in vasa not exposed to opiate drug in vitro, this concentration of normorphine never depressed the e.j.p. in vasa from morphine-pretreated
mice.

The effect of normorphine (3

~M)

was not changed by exposure of

the tissue to normorphine in vitro, whereas it was significantly decreased by exposure of the tissue to morphine in vivo.

Thus the expo-

sure of the vas deferens to high concentrations of morphine in vivo,
and not its maintenance in normorphine (300 nM) in vitro, produced the
tolerance to the effect of normorphine on transmitter release.
At the time the morphine-pretreated mice were killed and their
vasa removed for experimentation, blood levels of morphine probably
were in the

~M

range (see above).

However, the vasa were maintained
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in vitro in Krebs solution containing a lower concentration of normorphine (300 nM).

The tissues would therefore be in a state of partial

withdrawal during subsequent experimentation.

Perhaps the degree of

tolerance to morphine attained in vivo by the vas deferens is even
greater than was measured in vitro, after the tissue had been partially
withdrawn.

Normorphine at the concentration used in the present study

(300 nM) was able to prevent complete withdrawal of the tissue, because
tissues maintained under these conditions were still highly tolerant to
normorphine (Figure 12) and responsive to naloxone (Figure 14).
Morphine pretreatment of mice produced a decreased sensitivity to
normorphine of neuro-effector transmission in the vas deferens.

Did

this treatment also produce tolerance to other substances which decrease transmitter release at this site?

Adenosine inhibits both

3
neurally-evoked contractions of the muscle and [ H]-noradrenaline release from the isolated vas deferens of the rat.

Furthermore, the

responses to exogenous noradrenaline are not affected by adenosine;
this indicates a prejunctional site of action (Clanachan, Johns &
Paton, 1977).

The effect of adenosine on the e.j.p. in the mouse vas

deferens was investigated so as to determine whether prolonged exposure to morphine brought about changes in the sensitivity of the
intramural nerves to adenosine as well as to morphine.

Adenosine

depressed the e.j.p., but its ability to do so was not changed by
morphine pretreatment.

That is, morphine pretreatment led to tolerance

to the action of morphine without cross-tolerance to adenosine.
Similarly, implanting mice with morphine pellets for 3 days does not
alter the presynaptic inhibitory effect of the aadrenergic agonist
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clonidine (Robson, Gillan, Waterfield & Kosterlitz, 1978).
4.43

Manifestation of "dependence" - effect of naloxone
Naloxone did not change the resting membrane potential of the

smooth muscle cells of vasa from morphine-pretreated mice.

However,

naloxone did cause a large increase in the amplitude of the evoked
e.j.p. in those vasa.

Was this simply a reversal of the ongoing

depression of the e.j.p. by the normorphine present in the bathing
solution?

Two factors suggest not.

First, the vasa should have been

tolerant to 'the normorphine concentration (300 nM) present in the bath
fluid because a higher concentration of normorphine (1
depress the amplitude of the e.j .p.

~M)

did not

Second, the increase in e.j .p.

amplitude observed upon administration of naloxone to the vasa from
morphine-pretreated mice was marked (3.5 to 7-fold).
increase in amplitude was 360 + 37%.

The average

When naloxone was used to reverse

the depression caused by a short-lasting (10 min) application of normorphine (300 nM) to vasa from naive mice, the e.j.p. amplitude returned only to its control level before application of drugs.
represented an increase in e.j.p. amplitude of 64

This

± 11%.

It is possible that the exposure to normorphine (300 nM) in vitro
was the cause of the increased response to naloxone in vasa from
morphine-pretreated mice.

Therefore naloxone was also tested on

control vasa which were maintained for 5-8 hours in Krebs solution containing normorphine (300 nM).

Cells from these preparations responded

to naloxone (300 nM) with an increase in e.j.p. amplitude of 184 + 21%.
There was a significant change in the effectiveness of naloxone on
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e.j .p. amplitude as the duration of exposure to opiate increased, if
the responses of naive vasa exposed to opiate for 10 minutes, the
responses of naive vasa maintained in opiate for 1-5 hours, and the
responses of vasa from morphine-pretreated animals are compared (oneway analysis of variance:

p<O.Ol).

There was thus a trend toward

increased responsiveness to naloxone as the duration of exposure to
opiate drug increased.
An increase in the effectiveness of naloxone as a function of

duration of exposure to opiates has been observed in whole animal
studies, as well as in other in vitro preparations.

The dose-response

curve for morphine for producing antinociception in the tail-flick
test in mice was shifted to the right if naloxone (160

~g/kg)

administered concurrently with the test dose of morphine.

was

The dose-

response curve was shifted to a greater extent in mice that have been
pretreated with morphine (30 mg/kg) 3 hours before testing.
phine

Ec 50

1974a).

The mor-

was not changed by this pretreatment (Tulunay & Takemori,

Furthermore, in animals rendered tolerant to morphine by

multiple injections or by implantation of morphine pellets, naloxone
(160 pg/kg) also increased the morphine

Ec 50 ,

and the sensitivity to

this effect of naloxone was greater than in animals that have been
acutely treated with morphine.

The increase in the efficacy of nalo-

xone observed after morphine treatment appeared before tolerance to the
antinociceptive activity of morphine developed, and the efficacy of
naloxone increased faster than the development of tolerance (Tulunay &
Takemori, 1974b).

In another series of experiments, slices of corpus

3
striatum were incubated in Krebs solution containing [ H]-morphine, and
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the overflow of label during subsequent superfusion with drug-free
solutions was measured.

The addition of naloxone (1-100 pM) to the

superfusate resulted in a dose-related increase in the overflow of
label.

The sensitivity to this effect of naloxone was increased in

slices from mice given morphine pretreatment, either by a single
injection of morphine (100 mg/kg) 3 hours before the animal was
killed for experimentation, or by pellet implantation 3 days before the
experiment.

The time course for the development of the enhanced

potency of naloxone in striatal slices paralleled the time course for
the development of tolerance in the whole animal, as assessed by the
tail-flick method (Kitano & Takemori, 1979).
A time-dependent increase in naloxone sensitivity also occurs in
the guinea-pig ileum.

In this tissue, a naloxone-precipitated muscle

contracture is the manifestation of withdrawal from opiate drugs (see
North & Karras, 1978a).

Naloxone can induce a muscle contracture in a

tissue removed from a naive guinea-pig if this tissue is maintained in
Krebs solution containing normorphine (200 nM).

The degree of tension

developed by the muscle in response to naloxone increases as time of
exposure to normorphine increases.

The effect of naloxone is much

enhanced in tissues removed from morphine-dependent animals and maintained in morphine solution (Schulz & Herz, 1976).

In the present

experiments, the increase in e.j.p. amplitude caused by naloxone in
vasa exposed to normorphine (300 nM) was also much greater if the
tissue was removed from morphine-pretreated mice as distinct from
naive mice.

Large increases in e.j .p. amplitude were also observed in
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tissues from morphine-pretreated mice if the superfusing solution was
changed from one containing opiate (normorphine - 300 nM) to another
that was drug-free.

These increases were not as large or as consistent

as those obtained by superfusion with naloxone.

The large increase in

e.j .p. amplitude elicited by naloxone in vasa from morphine-pretreated
mice may be analogous to the muscle contracture in the guinea-pig
ileum.

The increase in sensitivity to naloxone of the nerve terminals

in the mouse vas deferens may therefore represent "dependence" on morphine in this tissue.
Normorphine inhibits evoked but not spontaneous release of transmitter from the sympathetic nerves in the mouse vas deferens:

the

amplitudes of evoked e.j.ps are depressed (Henderson & North, 1976) but
the frequency and amplitudes of spontaneous e.j.ps are not modified
(Henderson, 1976).

In the present study naloxone did not cause a large

increase in the spontaneous release of transmitter from the nerve
terminals of vasa from morphine-pretreated mice.

Such a massive

release would have been observed either as a depolarization of the
smooth muscle cells or as a burst of firing of spontaneous e.j.ps:
neither occurred.

Thus, it is reasonable that naloxone-precipitated

"withdrawal" in the mouse vas deferens is manifest as a dramatic increase in evoked release of transmitter (amplitude of evoked e.j.p.)
but not as a change in spontaneous transmitter release.
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4.44

Conclusions
The precise nature of the change in neuro-effector transmission

in the mouse vas deferens caused by prolonged exposure to morphine in
vivo is not known.

Clearly, though, the change takes place in the

nerve terminals which are sensitive to the action of morphine.

These

nerve terminals become tolerant to the depressant action of morphine on
transmitter release.

The postsynaptic cells which are not opiate-

sensitive did not exhibit changes in resting membrane potential or in
sensitivity to transmitter.

These findings do not support theories of

opiate tolerance and dependence which invoke changes in postsynaptic
sensitivity following blockade of transmitter release (Collier, 1968).
It will be of interest to see if tolerance develops in the mouse
vas deferens as a consequence of in vitro as well as in vivo exposure
to opiates.

The development of tolerance in vitro has been demon-

strated in the guinea-pig ileum (Hammond, Schneider & Collier, 1976;
North & Karras, 1978b) and in explants of fetal mouse spinal cord in
tissue culture (Crain, Crain, Finnigan & Simon, 1979).

The degree of

tolerance to the depressant action of opiates on transmitter release in
the mouse vas deferens can be easily quantified by measuring changes in

Ec 50

values.

This technique would thus be a sensitive way to assess

the effectiveness of treatments purported to alter the development of
opiate tolerance in other systems, such as protein synthesis inhibitors
(see Smith, 1971), peptides (Walter, Ritzmann, Bhargava & Flexner,
1979), cyclic nucleotides

(Hammond~

temperatures (Crain et al., 1979).

al., 1976) and low incubation
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4.5

Cyclic AMP and inhibition of transmitter release by opiates
The proposal that

~~

is involved in excitation-secretion

coupling in nerve terminals has been examined at both somatic and autonomic neuro-effector junctions.

Cyclic AMP has also been considered as

a mediator of the presynaptic alterations of transmitter release from
sympathetic nerves induced by 8-adrenergic agonists, serotonin and, in
the present study, opiates.

4.51

Role of cAMP in transmitter release
Calcium is required for the evoked release of transmitter from

nerves, but is an increase in the intraterminal concentration of cAMP
also a prerequisite?

Can

c~~

alter the amount of calcium entering

nerve terminals in response to a depolarizing stimulus, or the effectiveness of calcium in promoting transmitter release?

Cyclic AMP,

dbcAMP and IBMX potentiate the electrically-induced but not the spon3
taneous release of [ H]-dopamine from slices of rat neostriatum
(Westfall, Kitay & Wahl, 1976).

The role of cAMP in transmitter re-

lease has also been examined on peripheral nerves.

In the isolated rat

diaphragm-phrenic nerve preparation, dbcAMP and theophylline increase
the amplitude of the end-plate potential by a prejunctional action on
the cholinergic nerve terminal (Goldberg & Singer, 1969).

Systemic

administration of dbcAMP, theophylline or NaF (an activator of adenylate cyclase) induces spontaneous activity and increases the stimulusevoked response of single motor axons of cat soleus nerve in vivo
(Dretchen, Standaert, Skirboll & Morganroth, 1976).

A possible
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mechanism for this effect is a facilitation by cAMP of calcium influx
into the motor axons (Skirboll, Baizer & Dretchen, 1977; Skirboll,
Standaert & Dretchen, 1979).
Cyclic nucleotides and phosphodiesterase inhibitors also can
enhance autonomic neurotransmission.

In the isolated perfused spleen,

the monobutyryl derivative of cAMP (mbcAMP) and the phosphodiesterase
inhibitors IBMX, papaverine and RO 20-1724 enhance the nerve-evoked
3
overflow of [ H]-noradrenaline and dopamine-S-hydroxylase (DSH)
(Cubeddu, Barnes & Weiner, 1974 & 1975).

The effect of the phospho-

diesterase inhibitors on evoked noradrenaline release from the spleen
does not, however, correlate with their potencies in causing inhibition
of splenic phosphodiesterase (Cubeddu et al., 1974; Stjarne, 1979).
Also, a derivative of cGMP (8-bromo-cGMP) is as effective in this
action as the cAMP analogs (Cubeddu

~

al., 1975).

Wooten, Thoa,

Kopin & Axelrod (1973) report an enhancement of the evoked release of
3
[ H]-noradrenaline and DSH from the guinea-pig vas deferens by dbcAMP
(100

~M)

or theophylline (1 mM).

These results could not be repeated

by another investigator (Stjarne, 1976).

Differences in stimulation

parameters and the difficulty of accurately measuring the small amount
of DSH released from the vas deferens could account for the discrepancy
(Stjarne, 1976 & 1979).

Stjarne, Bartfai & Alberts (1979) saw an

3
enhancement of nerve-evoked secretion of [ H]-noradrenaline from the
guinea-pig vas deferens in the presence of another analog of cAMP
(8-bromo-cAMP) and more specific inhibitors of phosphodiesterase (IBMX
and SQ 20,006).

None of these studies at either somatic or autonomic
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nerve-muscle junctions offers conclusive evidence that cAMP is an
essential intermiediate in excitation-secretion coupling.

But the

presence of cyclic nucleotide derivatives and phosphodiesterase inhibitors, which may produce alterations in the concentration of cAMP in
nerve terminals, appears to modify transmitter release at some sites
under some experimental circumstances.
In the present study, cAMP and dbcAMP depressed rather than
enhanced e.j.p. amplitude in the mouse vas deferens.

Because cAMP does

not readily penetrate cell membranes, the effect of this substance
probably is a result of interaction with adenosine receptors located
extracellularly on the presynaptic nerve terminals (Clanachan et al.,
1977).

Dibutyryl cAMP more readily crosses cell membranes and hence

less would remain in the extracellular fluid to activate those receptors.

The relative potencies of adenosine, cAMP and dbcAMP for inhibi-

tion of e.j.p. amplitude in the mouse vas deferens (adenosine>cAMP>
dbcAMP) match their relative potencies for action on adenosine receptors in the guinea-pig ileum (Sawynok & Jhamandas, 1976).

In the

latter tissue these purine compounds reduce the output of acetylcholine
in response to. electrical stimulation of the nerves (Takagi &
Takayanagi, 1972).

Because adenosine inhibits evoked noradrenaline

release from the rat vas deferens (Clanachan et al., 1977) and the cat
spleen (Mueller, Mosimann & Weiner, 1979), a similar action of compounds acting on the adenosine receptors of the mouse vas deferens is
assumed.
The increase of e.j.p. amplitude by IBMX and SQ 20,006 in the
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present study is likely to be a presynaptic action on the nerve terminals because these compounds enhance the stimulation-evoked release of
noradrenaline and DSH at other sympathetic junctions (see above).

A

postsynaptic sensitization of the smooth muscle membrane to transmitter
is another possible action, which unfortunately could not be disproved.
IBMX alone or combined with dbcAMP inhibited the contractile response
of the smooth muscle of the mouse vas deferens to both noradrenaline
and potassium ion, suggesting a direct interference with excitationcontraction coupling.

Postsynaptic actions of phosphodiesterase

inhibitors have previously been observed with the pressor response of
splenic vasculature (Cubeddu

~

al., 1974) and the contractile response

of the guinea-pig vas deferens (Stjarne et al., 1979).
Is the effect of IBMX on e.j.p. amplitude a result of inhibition
of phosphodiesterase or is it caused by another action of this compound?

The structure of IBMX is that of a methylxanthine, and methyl-

xanthines such as theophylline increase the entry of calcium across
cell membranes (Blinks, Olson, Jewell & Braveny, 1972), mobilize calcium from intracellular storage sites (Johnson & Inesi, 1969) and
potentiate calcium-dependent ionic currents, independent of an inhibition of phosphodiesterase (Smith, Weight & Lehne, 1979).

Methyl-

xanthines also antagonize the actions of adenosine (Sattin & Rall,
1970) and prostaglandins (Horrobin, Manku, Franks & Hamet, 1977).

Al-

though the effect of IBMX in the mouse vas deferens could be caused by
any of these actions, it is more likely to be the result of inhibition
of phosphodiesterase for several reasons.

The non-xanthine phospho-
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diesterase inhibitor SQ 20,006 had the same effect.

Also, IBMX and

dbcAMP applied simultaneously were more effective than IBMX alone.

In

one cell dbcAMP was applied after the preparation had been superfused
with IBMX for several minutes: -in this cell dbcAMP increased e.j.p.
amplitude.

In the absence of phosphodiesterase inhibition the increase

in cAMP caused by hydrolysis of intracellular
by endogenous phosphodiesterase.

dbcfu~

may be prevented

Phosphodiesterase inhibitors (IBMX or

SQ 20,006) would protect the released cAMP from metabolism.
effects of IBMX and dbcAMP would be complementary.

Thus the

Lastly, IBMX en-

hances transmitter release in another preparation (molluscan neurons),
an action which can be mimicked by intracellular injection of cAMP
(Klein & Kandel, 1978).
4.52

Cyclic AMP and presynaptic modulation of transmitter release
The enhancement of transmitter release from sympathetic nerve

terminals by e-adrenergic agonists may be mediated by an increase in
the intraterminal concentration of cAMP.

Celuch, Dubocovich & Langer

(1978) report that both e-adrenergic agonists and phosphodiesterase
3
inhibitors (papaverine and IBMX) enhance the overflow of [ H]-noradren-

aline induced by nerve stimulation in the perfused cat spleen.

Pro-

pranolol reduces the effect of the phosphodiesterase inhibitors, as
well as the effect of the S-adrenergic agonists.

This suggests that

the phosphodiesterase inhibitors may be enhancing the action of endogenous noradrenaline which, after its release, is interacting with S
receptors on the nerve terminals.

The S-adrenergic agonists isoprena-
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line and terbutaline also enhance the potassium-evoked release of noradrenaline from the pineal gland, an action shared by dbcAMP (Pelayo,
Dubocovich & Langer, 1978).

Also, a selective inhibitor of cAMP-

specific phosphodiesterase enhances noradrenaline release in pineal
glands in which the presynaptic a-adrenergic receptors are blocked by
yohimbine.

The action of another presynaptic modulator, serotonin, may

also be mediated by cAMP at a particular ganglionic synapse of Aplysia.
Presynaptic facilitation of transmitter release at this synapse by a
sensitizing stimulus in a sensory nerve pathway is simulated by extracellular application of serotonin or dbcAMP or by intracellular injection of

c.~

(Kandel, Brunelli, Byrne & Castellucci, 1976).

The involvement of cAMP in the inhibition by opiates of transmitter release from axon varicosities of the mouse vas deferens was
tested in the present study.

Caution is warranted in the interpreta-

tion of results from vasa exposed to cyclic nucleotides (cAMP or
dbcAMP) because these substances may have postsynaptic effects on the
smooth muscle membrane, perhaps altering the sensitivity to the transmitter noradrenaline.

Postsynaptic effects of the nucleotides on the

response to noradrenaline could not be tested because, like IBMX, these
substances inhibit excitation-contraction coupling in smooth muscle.
Exposure of the vas deferens to cAMP (1

~~),which

depressed the ampli-

tude of the e.j.p., did not alter the potency of normorphine in causing
a further depression of transmitter release.

These compounds are

acting at different receptors, cAMP at the adenosine receptor (see
above) and normorphine at the opiate receptor.

Substances which bind

to these receptors are unlikely to have a common mode of action because

169
tolerance to the action of opiates is not accompanied by tolerance to
the action of adenosine (see above).

This result does not support the

conclusions of studies which purport to show antagonism of the action
of morphine by administration of cAMP (Ho

~

al., 1973).

The effect of

normorphine also was unaltered by the drug combination IBMX + dbcAMP.
The increase in transmitter release in the presence of this combination
may reflect an increase in the intraterminal levels of cAMP (see
above).

If this is the case, then the potency of the narcotic does not

depend on the concentration of cAMP in the nerve terminals which bear
the opiate receptors.

Enkephalins are more potent than narcotics as

inhibitors of transmitter release in the mouse vas deferens (Lord et
al., 1977).

The enkephalin analog DAEA was more potent than normor-

phine in depressing e.j.p. amplitude, but its effect was also not
blocked by IBMX + dbcAMP in concentrations which produced an even
greater enhancement of e.j.p. amplitude and, presumably, intraterminal
cAMP concentrations.
Neurotransmission in the mouse vas deferens is much more sensitive to inhibition by a-type opiate agonists than by
~

al., 1977).

~

agonists (Lord

Furthermore, the most direct demonstration that opiates

alter cAMP levels comes from studies of hybrid neuroblastoma x glioma
cells grown in tissue culture, and the opiate receptors on these cells
are almost exclusively of the a-type (Chang, Cooper, Hazum &
Cuatrecasas, 1979).

Thus it is possible that cAMP is involved only in

the actions of opiates mediated by a receptors, and not the actions
mediated

by~

receptors.

This is not likely because the depression of

the e.j.p. by the specific 8 agonist DADL was not changed by IBMX +
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dbcAMP.
Is it possible that the acute effects of opiates are mediated by
a decrease in neuronal cAMP concentrations, but other factors can
account for the inability of cyclic nucleotides and IBMX to block the
action of opiates in the mouse vas deferens?
stances (IBMX,

dbcA}~)

Firstly, are these sub-

actually increasing the cAMP concentrations at

the transmitter release sites in the axon varicosities?

The evidence

that they are is indirect because the anatomy of the vas deferens precludes the direct measurement of cAMP levels in the nerve terminals.
The concentrations of IBMX used in the present study (50 ~M, 500 ~M)
are probably high enough to inhibit cAMP phosphodiesterase because in
other systems the IC
is approximately 5

50

~M

for inhibition of cAMP phosphodiesterase by IBMX
(Beavo, Rogers, Crofford, Hardman, Sutherland &

Newman, 1970; Collier et al., 1976).

Furthermore, similar concentra-

tions of IBMX do increase cAMP levels in other tissues (neuroblastoma
cells:

Hamprecht & Schultz, 1973; slices of anterior pituitary gland:

Schofield & McPherson, 1974).

Also, the effectiveness of the drug

combination IBMX + dbcAMP in enhancing transmitter release in the mouse
vas deferens (see above) suggests that these substances are directly or
indirectly affecting the transmitter release sites in the varicosities.
The action of opiates on transmitter release may result instead
from alterations in cGMP levels in the varicosities.

There is evidence

that in the rat pineal gland the inhibition of the release of noradrenaline by a-adrenergic agonists is mediated by an increase in the cGMP
levels of noradrenergic nerve endings

(Pelayo~

al., 1978).

In this

context it is of interest that withdrawal of a tolerant guinea-pig
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ileum from morphine renders the preparation insensitive to clonidine,
an a-adrenergic agonist that usually is a potent inhibitor of the
evoked release of acetylcholine (Robson et al., 1978).

Similarly, the

ratio of cAMP to cGMP may be important in the actions of opiates, and
not the absolute level of either one.

IBMX inhibits hydrolysis of cGMP

(Kakiuchi, Yamazaki, Teshima, Uenishi & Miyamoto, 1975) as well as
hydrolysis of cAMP, and thus may not alter this ratio in the adrenergic
nerves so as to block the action of morphine.

Further experimentation

is needed to confirm or refute this hypothesis that cGMP and not cAMP
mediates the inhibition of transmitter release by opiates in the mouse
vas deferens.
Opiates inhibit transmitter release in the mouse vas deferens by
a presynaptic action on the adrenergic nerves.

Another major action of

opiates is depression of the firing rate of single neurons.

The com-

bined presence of IBMX + dbcAMP was unable to alter the acute inhibitory action of morphine on the firing rate of single myenteric neurons
of the guinea-pig ileum (Karras & North, 1979).

The opiate-sensitive

neurons of both the mouse vas deferens and the guinea-pig ileum are
peripheral in location.

The effect of"cAMP on the actions of opiates

on central neurons in vivo has also been tested, and the results are in
agreement with the results obtained using peripheral neurons.

Thus,

the depression by iontophoretically-applied morphine of the activity of
lamina V cells in the spinal cord is unaffected by the simultaneous
iontophoresis of IBMX or of dbcAMP (Duggan & Griersmith, 1979).
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In the neuroblastoma x glioma hybrid cells, opiates acutely decrease cAMP concentrations, but prolonged exposure to opiates produces
tolerance to this effect in that the cAMP concentrations return to
normal despite the continuous presence of opiate drug (Sharma et al.,
1975b).

It has been suggested (Karras & North, 1979; Collier, 1980)

that cAMP is involved in the chronic but not the acute actions of
opiates.

There is evidence against the involvement of cAMP in the

acute actions of opiates on transmitter release (present study) and
on the firing rate of single neurons (Karras & North, 1979; Duggan &
Griersmith, 1979).

The involvement of cAMP in the long-term effects

of morphine, that is, the development of tolerance and dependence,
remains to be tested.
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4.6

Calcium ion and inhibition of transmitter release by opiates

4.61

Presynaptic modulation of transmitter release:

role of calcium

Transmitter release is a function of the concentration of calcium
ion at release sites within nerve terminals.

Therefore it has been

proposed that substances which modulate transmitter release alter
calcium availability or action at these sites.
The release of noradrenaline from sympathetic nerve endings can
be inhibited by a-adrenergic agonists, muscarinic agonists and prostaglandins (see reviews by Starke, 1977; Westfall, 1977).

The effects

of these substances on transmitter release have several features in
common.

First, only noradrenaline release that is dependent on the

presence of extracellular calcium is inhibited.

Release evoked by

stimulation of nerves or by direct depolarization of nerve terminals
with high concentrations of potassium is sensitive, whereas spontaneous
or tyramine-induced release is insensitive.

Second, the degree of

inhibition by these substances appears to depend on the concentration
of calcium ion in the extracellular fluid; high calcium decreases and
low caJcium increases their effectiveness.

Lastly, these substances

are more potent at low as opposed to high frequencies of nerve stimulation.

The facilitation of transmitter release that occurs at high

frequencies of stimulation has been explained by an increase in the
amount of calcium available at the transmitter release sites (Younkin,
1974).

These findings are interpreted as evidence that calcium has a

pivotal role in presynaptic inhibition.
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The inhibition of transmitter release by opiates is also considered to be mediated by a decrease in calcium availability for
similar reasons.

Thus, in the mouse vas deferens morphine depresses

the release of noradrenaline evoked by nerve stimulation (Henderson
et al., 1972) or high potassium solutions (Sim & Henderson, personal
communication), but not the spontaneous release of noradrenaline
measured either biochemically (Hughes et al., 1975a) or electrophysiologically (Henderson, 1976).

Spontaneous transmitter release

is not dependent on the extracellular calcium ion concentration
(Hashimoto & Holman, 1967; Hubbard, Jones & Landau, 1968; Rubin, 1970).
Also, the depression by morphine of the neurally-mediated contractions
of the smooth muscle and of the release of noradrenaline from the
adrenergic varicosities of the mouse vas deferens is frequencydependent; morphine is more potent at low than at high frequencies of
nerve stimulation (Henderson & Hughes, 1976).

At other sites of neuro-

transmission which are sensitive to opiates, the potency of the opiates
appears to depend on the extracellular calcium ion concentration.

For

example, DAEA depresses the amplitude of e.p.s.ps evoked by preganglionic stimulation of prevertebral sympathetic ganglia, an effect
that is more marked in low calcium (0.7 mM)-high magnesium (2 mM)
solutions than in solutions containing higher concentrations of calcium
ion (Konishi, Tsunoo & Otsuka, 1979).

Also, opiates depress the

negative slow waves recorded in fetal explants of mouse spinal cord
during stimulation of the attached dorsal roots; this action is reduced
in high calcium solutions (3-5 mM vs. 1 mM) (Crain, Crain, Peterson &
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Simon, 1978).
More direct evidence for modulation of calcium currents by substances that presynaptically alter transmitter release has been provided by studies of ganglion cells in vitro.

The action potential of

the soma of immature chick dorsal root ganglion cells has a calciumdependent plateau phase which is accentuated in high calcium solutions
or in solutions containing barium (Dichter & Fischbach, 1977).

The

duration of this plateau phase is shortened by noradrenaline and serotonin (Dunlap & Fischbach, 1979), as well as by the opioid peptide DAEA
(Mudge, Leeman & Fischbach, 1979).

This effect of DAEA on the ganglion

cell bodies correlates with its inhibition of the release of substance
P from the nerve terminals of these cells, although the postulate that
the same mechanism is responsible for both effects is inference.

It is

unlikely that the membranes of a neuron's cell body and its axon terminals are identical with respect to distribution, density and properties of ionic channels as well as susceptibility of those channels to
external regulation.

The presence of high calcium concentrations is

required to demonstrate clearly the effect of the opioid peptide in
these cells, whereas transmitter release is purported to be less
sensitive to inhibition by opiates under these conditions (see above).
Also, the alteration of the action potential plateau could result either
from a decrease in the inward calcium current or an increase in an outward potassium current.

A change in the inward calcium current during

presynaptic inhibition could be measured by impaling nerve terminals
and voltage-clamping their membrane potential.

Studies at an inverte-
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brate synapse come closest to achieving this ideal situation.

In the

abdominal ganglion of Aplysia, presynaptic inhibition of transmitter
release from the identified cholinergic cell 110 occurs in response to
stimulation of specific sensory fiber pathways.

Transmitter release

can be assayed by measuring the amplitude of synaptic potentials in
follower cells of the 110 neuron.

If the 110 neuron is voltage-clamped

in the presence of tetrodotoxin, depolarizing pulses elicit graded
transmitter release, suggesting at least partial control of the membrane potential of the nerve terminals (Shapiro, Castellucci & Kandel,
1980a).

These step depolarizations of the soma, if carried out during

pharmacological blockade of sodium channels (with tetrodotoxin) and
potassium channels (with the combination of tetraethylammonium ions,
4-aminopyridine and barium), elicit an inward current carried presumably by calcium ions.

During presynaptic inhibition caused by stimu-

lation of the sensory pathway, the transient inward calcium current·
elicited by step depolarizations is decreased (Shapiro et al., 1980b).

--

The mouse vas deferens preparation offers no convenient way of
assessing the effect of opiates on the transient calcium

c~rrents

associated with transmitter release from the axon varicosities.

There-

fore the amplitude of the e.j.p. was used as a measure of transmitter
release and the ability of normorphine to depress this transmitter
release was measured in the presence of different calcium ion concentrations.

Halving or doubling the calcium ion concentration led to

marked changes in the amount of transmitter released.

However, the

ability of normorphine to depress transmitter release \vas little
changed by these manipulations.
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It may be argued that a different population of nerves was
excited in the solutions with altered calcium ion concentration.
Stimulus voltage was adjusted to compensate for the effect of
altered calcium in order to obtain control e.j.ps of approximately
the same amplitude.

However, if the stimulus voltage was not adjusted,

normorphine was equally effective in low and in control calcium
solutions, even though the pre-drug e.j.p. amplitudes differed.

As

already discussed, the potency of normorphine is independent of the
initial amplitude of the e.j.p.
If the· effects of normorphine on e.j.p. amplitude as summarized
in Table 5 are reevaluated so that corrections for non-linear summation
are made, then in some cells normorphine (1
normal (2.54

m~)

~M)

is more effective in

calcium than in low (1.27 mM) calcium.

However, the

depression of transmitter release by normorphine was not different in
normal vs. low calcium if the results are averaged and a statistical
comparison made (Table 7).
4.62

Effect of calcium on e.j.p. amplitude- loci of action
Could the alteration in e.j.p. amplitude by calcium ion be

explained by actions at sites other than at the adrenergic varicosities
which are releasing the transmitter?

Calcium alters neuronal excita-

bility by shifting the voltage sensitivity of the system controlling
membrane permeability to sodium and potassium; in high calcium, nerves
are stabilized and in low calcium, nerves are more excitable
(Frankenhaueser & Hodgkin, 1957).

By reducing the number of nerves

excited, elevated calcium might reduce e.j.p. amplitude, whereas in low
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Table 7.

Effect of normorphine (1 ].lM) on "transmitter release"

(corrected for non-linear summation) in normal and low calcium:
same cell.

Results of Table 5 are corrected to account for non-

linear summation using the conversion formula of Table 6.*

Depression of "transmitter release"
by normorphine (1 ].lM)
Cell I!

Calcium (2.54 mM)

Calcium (1.27 mM)

7259-3

-83%

-89%

8bl9-5

-76%

-71%

8149-5

-92%

-69%

10169-4

-88%

-77%

10179-1

-90%

-90%

-86 + 2.9%

-79 + 4.5%

*There was no difference in the amount of depression of "transmitter
release" by normorphine (1 ].lM) in normal calcium (2 .54 mM) vs. low
calcium (1.27 mM) in the same cell (Student's t test, p>O.OS).

179
calcium more nerves would be excited by a given stimulus voltage, and
e.j.p. amplitude would increase.

But the relationship between e.j.p.

amplitude and external calcium ion concentration in the present experiments was in the opposite direction.
Another possible locus of action of calcium ion in the mouse vas
deferens is on the bioassay system used, the postsynaptic smooth muscle
cells.

The reaction of transmitter with the postsynaptic membrane may

be changed.

The membrane potential of smooth muscle cells is hyper-

polarized by excess calcium and depolarized by a decrease in calcium
(Bulbring & Kuriyama, 1963).

These changes occur without modification

of the ionic content of the cell (see Casteels, 1970).

Meaningful

measurements of the resistance of the resting or active smooth muscle
membrane as a function of the external calcium ion concentration cannot
be made with a single microelectrode.

Thus any effect on e.j.p. ampli-

tude of calcium-mediated alterations of membrane potential and resistance cannot be determined.

However, these effects are likely to be

small because the manipulations of calcium ion concentration did not
change the membrane potential by more than 5 mV in the present experiments.

The most likely site of action of calcium is thus the nerve

terminal - a direct change in the stimulus-evoked transient inward
calcium current that produces release of transmitter.

Bennett &

Florin (1975) previously reported that the amplitude of the e.j.p. in
the mouse vas deferens is dependent on the extracellular calcium ion
concentration.

In their experiments the synaptic potential increased

with about the second power of the extracellular calcium ion concentration.
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4.63

Interactions between calcium and opiates
In the mouse vas deferens, both normorphine (Henderson & North,

1976) and the calcium ion (Bennett & Florin, 1975) change the amplitude
of the e.j.p. by acting at the same locus, the presynaptic nerve
terminal.

But the potency of normorphine is independent of the calcium

ion concentration over a four-fold range (1.27-5.08 mM).
allow two conclusions to be drawn.

These results

First, the affinity of normorphine

for the opiate receptor and the efficacy of the resulting drug-receptor
complex are ?Ulikely to be calcium-dependent.

Second, considerable

caution is warranted in the interpretation of studies of complex
neuronal assemblies such as the central nervous system in vivo or a
plexus of neurons in vitro, which claim to demonstrate antagonism of
the effects of opiates by calcium.

The interaction in these systems

may be a functional antagonism which does not allow conclusions to be
drawn concerning the mechanism of action of opiates.
The action of opiates has also been tested in neuroblastoma x
glioma hybrid cells exposed to differing concentrations of extracellular calcium ion.

Opiates and opioid peptides decrease cAMP levels

in these cells even if calcium ion is omitted from the incubation
medium.

5
The inhibition by Leu -enkephalin of PGE -induced increases in
1

cAMP levels is independent of the extracellular calcium ion concentration over a wide range (1

~M-

20 mM) (Brandt, Buchen & Hamprecht,

1980).
How can the results in neuroblastoma x glioma hybrid cells
(above) and the mouse vas deferens (present experiments) be reconciled
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with the experimental evidence in favor of a major role for calcium ion
in the actions of opiates?

Opiates inhibit calcium uptake into brain

synaptosomes (Guerrero-Munoz et al., 1978).

In lysed synaptosomes,

morphine inhibits only active (ATP-dependent) calcium uptake (GuerreroMunoz~

calcium

al., 1979).
(~

= 0.85

Furthermore, a high affinity binding site for

~M)

affected by opiates.

located on synaptic membranes is selectively
The binding of calcium to this site is inhibited

by preincubation of membranes in levorphanol (0.5-10 nM) and, furthermore, levorphanol can release calcium that has already been bound (Ross

& Cardenas, .1977).

Perhaps the high affinity, saturable calcium

binding and the ATP-dependent calcium uptake are the same functional
system.

This system would be located on the inner surface of the

synaptic membrane.

It would be in some way coupled to extracellularly

located opiate receptors such that binding of opiates to their receptors would inhibit calcium uptake and binding.

The function of such a

system might be to maintain a low calcium ion concentration in a particular sub-compartment of the intracellular space.

Opiates could act by

increasing the calcium ion concentration of this compartment.

Such an

action could reduce the evoked release by transmitter in two ways.
Firstly, the driving force for calcium entry during depolarization of
the synaptic membrane could be reduced.

Secondly, a calcium-dependent

process could be activated which would, in turn, reduce transmitter
release.

One possible candidate is the calcium-dependent potassium

conductance which has been demonstrated in several neuronal systems
(see Thompson, 1977).

An increased conductance to potassium ion would
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hyperpolarize the terminal or pre-terminal membrane and possibly prevent invasion of axon varicosities or by some other mechanism inhibit
transmitter release (see below) .
4.64

Mechanism of presynaptic inhibition by opiates:

speculation

Although the present findings provide evidence against an effect
of calcium on the action of morphine, they do not directly refute a
possible effect of morphine on calcium action in the nerve terminals.
Thus it is possible that morphine is blocking the entry of calcium
through its voltage-dependent channels, although if this blockade were
competitive, it might be expected to be critically dependent on the
external calcium ion concentration.

Opiates could directly decrease

the transient calcium current by completely closing some calcium
channels, by decreasing the conductance of all channels, or by increasing the voltage threshold at which they become activated.

The

calcium current could be indirectly depressed by decreasing the amplitude or shortening the duration of the presynaptic action potential.
At the squid giant synapse a decrease in the amplitude of the spike
of the presynaptic terminal causes a decrease in the amount of transmitter released from that terminal (Erulkar & Weight, 1977).

An

increase in an outward potassium current would shorten the action
potential duration and decrease the voltage-dependent calcium current.
Such a potassium current may or may not be calcium-dependent (Thompson,
1977).

Morphine could also leave unchanged the inward calcium current

and instead decrease the amount of calcium available for interaction
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with the transmitter release sites.

This could be accomplished by

increasing the affinity for calcium of another calcium-binding site in
the nerve terminal.
Another possible mechanism of action for presynaptic inhibitors
of transmitter release is blockade of impulse propagation into the fine
terminal ramifications of autonomic nerves.

Such a mechanism has pre-

viously been considered for the inhibition of transmitter release by
a-adrenergic agonists (Stjarne, 1978) as well as by opiates (Sastry,
1978; North, 1979b).

Blakeley & Cunnane (1979) provide electrophysio-

logical evidence that transmitter release from a given varicosity in
the vas deferens is intermittent, which could reflect a lack of activation of each nerve fiber by every impulse.

There is a large increase

in the membrane surface area through which activating ionic currents
must pass between the adrenergic axon and the nerve varicosity.

Such a

region would have a lower safety factor for impulse propagation, and
hyperpolarization of the membrane would further reduce the safety
factor (Van Essen, 1973).

Hyperpolarization of neurons by opiates has

been observed in the myenteric plexus of the guinea-pig ileum (see
North, 1979b), in the locus coeruleus (Henderson, personal communication) and in the frog sympathetic ganglion (Wouters & van den Bercken,
1979).

Afferent fibers of the sural nerve terminate in the dorsal horn

region of the spinal cord.

The excitability of the terminal region of

single Ao fibers of this nerve is decreased by morphine; hyperpolarization of the terminals could produce this effect (Sastry, 1978).
Although morphine does not alter the conduction of the action potential
in non-terminal regions of the hypogastric or vagus nerves (Kosterlitz
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& Wallis, 1964), the membrane of the terminal regions may have different properties.
in those regions.

Possibly functional opiate receptors are found only
Hyperpolarization by morphine of the terminal

portion of the preganglionic fibers of the frog sympathetic ganglion
has been reported (Wouters & van den Bercken, 1980).
Further experimentation with the mouse vas deferens and with
other tissues that have opiate-sensitive transmitter release will hopefully produce more evidence to explain how opiates depress the nerveevoked release of transmitter substances.

As the two predominant

effects of opiates in the central nervous system are depression of
the firing rate of neurons, and depression of transmitter release from
nerve terminals, such information will aid in the understanding of how
opiates produce their important pharmacological effects in man.
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4.7
4.71

Proposals for future experiments

Effects of prolonged exposure to opiates
The present experiments have demonstrated that in vivo exposure

of the mouse vas deferens to morphine results in the development of
tolerance to the effect of normorphine on transmitter release, as
assessed in vitro.

It is of interest to find out if prolonged in vitro

incubation of the vas deferens in morphine also leads to tolerance.

If

in vitro tolerance can be demonstrated, then factors which might enhance
or block tolerance could be studied.

Such factors, which are best

studied in in vitro as opposed to in vivo experiments, include length
of incubation time, incubation temperature, calcium ion concentration,
and the presence of cyclic nucleotides and phosphodiesterase inhibitors
or protein synthesis inhibitors.

Incubation of vasa in the presence of

2
5
D-Ala -D-Leu -enkephalin (DADL) would address the question of whether
tolerance develops to actions of opiates mediated by 8 receptors, as
well as to effects mediated
tolerance between

~

by~

receptors.

The extent of cross-

and 8 agonists could be quantitatively assessed in

tissues incubated in vitro with either a

~

agonist (morphine) or a 8 ·

agonist (DADL).
4.72

Cyclic nucleotides
The results of testing cyclic nucleotides and phosphodiesterase

inhibitors on e.j.ps in the mouse vas deferens raise many questions
about the role of cAMP in transmitter release and about the pharmacology of these substances.

More phosphodiesterase inhibitors should be
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tested on the e.j.p. to see if potency in increasing e.j.p. amplitude
is correlated with potency in inhibiting phosphodiesterase, and especially cAMP vs. cGMP specific phosphodiesterases.

In order to elimin-

ate any problems of interpretation related to possible postsynaptic
effects of these compounds, effects on transmitter release as assessed
by overflow studies could be measured.
It was observed that e.j.ps that had been increased in amplitude
by IBMX did not facilitate when the stimulation frequency was increased
(from 0.033 to 1Hz).
frequency of· 1Hz.

Facilitation usually occurs at a stimulation

The effect of phosphodiesterase inhibitors on

facilitation of transmitter release could be studied, and the role of
calcium ion in the action of phosphodiesterase inhibitors also examined.
The role of cyclic nucleotides in tolerance to opiates could be
tested by co-incubating vasa deferentia in phosphodiesterase inhibitors
or cyclic nucleotide analogs together with morphine in in vitro experiments (see above).

If such compounds do alter the development of

tolerance, then the relative specificities of cAMP vs. cGMP selective
phosphodiesterase inhibitors and cAMP vs. cGMP analogs could be investigated.
4.73

Calcium ion
Experiments which might further elucidate the possible role of

the calcium ion in the inhibition of transmitter release by opiates in
the mouse vas deferens include:
(1)

testing the effect of altered calcium ion concentration on e.j.p.
amplitude in the presence of opiates;
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(2)

measuring the post-stimulus increase in spontaneous potentials,
or the spontaneous potentials in the presence of elevated extracellular potassium ion concentration, and determining if opiates
change the frequency of these spontaneous events.

A component of

the spontaneous release under these latter two circumstances is
reportedly dependent on extracellular calcium; the calcium dependence of these phenomena would first have to be assessed by the
use of calcium channel blockers such as cobalt ion;
(3)

loading liposomes with calcium ion and applying them to tissues
bathed in zero calcium solution.

If transmitter can be released

by this method, the effectiveness of opiates on such release
could be tested.

An inhibition of liposome-induced transmitter

release by opiates would imply an action of opiates on a release
mechanism other than the depolarization-induced inward calcium
current, because liposomes deposit the calcium ion directly into
the intracellular compartment.

188
4.8
1.

Summary

Excitatory junction potentials were recorded by impalement of
single smooth muscle cells of the mouse vas deferens in vitro.
The amplitude of these potentials was used as a measure of the
release of transmitter, which is most likely noradrenaline, from
the varicosities in response to single pulse stimulation of the
intramural nerves.

2.

E.j.ps were depressed by application of opiates and opioid
peptides to the tissue.

The Ec

50

values were 560 nM for normor-

2
5
phine, 50 nM for D-Ala -Met -enkephalinamide (DAEA) and 500 pM
2
5
for D-Ala -D-Leu -enkephalin (DADL).
3.

The potency of normorphine (100 nM, 300 nM and 1

~M)

was the same

regardless of the control amplitude of the e.j.p. and of the
stimulus strength used to evoke the e.j.p.
4.

In order to study the effect of prolonged exposure to morphine on
neuro-effector. transmission in the vas deferens, two groups of
mice were studied.

One group was naive and the second group re-

ceived multiple injections of morphine sulphate (every 8 hours,
up to 140 mg/kg) for 3 days.

The vasa from morphine-pretreated

mice were maintained in Krebs solution containing normorphine
(300 nM).
5.

Prolonged exposure to morphine in vivo did not alter the resting
membrane potential of single smooth muscle cells nor the contrac-
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tile response of the smooth muscle to exogenous noradrenaline.
6.

E.j.ps were depressed by normorphine in vasa from both groups of
mice:

the Ec

50

was 560 nM for the naive group and 6.6

morphine-pretreated group.

~M

for the

This shift to the right of the nor-

morphine dose-response curve could not be accounted for by the
presence of normorphine (300 nM) in the Krebs solution of the
morphine-pretreated mice.
7.

Adenosine (300

~M

and 1 mM) depressed the e.j.p. with equal

potency in vasa from both groups of mice.
8.

Naloxone (300 nM) caused a marked (3.5 to 7-fold) increase in the
e.j.p. amplitude of vasa from morphine-pretreated mice.

The in

vitro exposure of these vasa to normorphine could not account for
this large effect.

It is believed that the increase in response

to naloxone of the nerve terminals may represent "dependence" on
morphine in this tissue.
9.

These results indicate that prolonged exposure of a mouse vas
deferens to morphine in vivo leads to the development of tolerance
to the normal inhibitory effect of normorphine on transmitter
release.

This "presynaptic" tolerance is not associated with

changes in resting membrane potential or sensitivity to transmitter of the postsynaptic smooth muscle cells.
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10.

The involvement of adenosine 3' ,5 1 -cyclic monophosphoric acid
(cAMP) in the action of opiates on transmitter release was tested
by measuring the effectiveness of opiates in the presence of
drugs which might elevate the cAMP concentrations in the nerve
terminals:

cAMP, dibutyryl cAMP (dbcAMP) and 1-methyl-3-iso-

butylxanthine (IBMX).
11.

Cyclic AMP and dbcAMP (1 mM) depressed the amplitude of the
e.j.p., possibly by interacting with extracellular sites similar
to those responsive to adenosine.

12.

The phosphodiesterase inhibitors IBMX (50 and 500
SQ 20,006 (500

~M)

~M)

and

increased e.j.p. amplitude; this increase was

much greater when the phosphodiesterase inhibitor was applied
together with dbcAMP.

It is believed that these increases in

e.j.p. amplitude represent a presynaptic action on transmitter
release, analogous to the effects of phosphodiesterase inhibitors
at other sites of neuro-effector transmission.
13.

There was no change in the

Ec 50

for normorphine in the presence

of cAMP (1 mM) or in the presence of the drug combination IBMX
(50

~M)

and dbcAMP (500

~M).

Similarly, the depression of the

e.j.p. by the opioid peptides DAEA and DADL was not affected by
the combination IBMX (500
14.

~M)

and dbcAMP (250

~M).

These findings provide evidence against the hypothesis that a
reduction in cAMP levels in the nerve terminals is an essential
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step in the inhibition by opiates and opioid peptides of transmitter release.
15.

It has been proposed that the presynaptic action of opiates may
result from a decrease in the depolarization-induced influx of
calcium ions that precedes the release of transmitter from nerve
terminals.

The action of normorphine in the mouse vas deferens

was therefore tested in tissues that were superfused with different concentrations of calcium ion.
16.

Doubling or halving the calcium ion concentration from its usual
value (2.54 mM) caused marked changes in the amplitude of the
e.j.p.

These alterations in the e.j.p. are likely to result from

an effect of calcium on transmitter release.
17.

In vasa superfused with different concentrations of calcium ion,
the stimulus strength was adjusted so that normorphine was tested
on e.j.ps of approximately the same amplitude.

Under these

conditions the ability of normorphine to depress the e.j.p. was
little changed in tissues superfused with calcium (1.27-5.08 mM).
18.

In cells in which the stimulus strength was not adjusted when the
calcium ion concentration was changed, normorphine (1
effective in normal (2.54 mM) as in one-half (1.27

19.

w~)

~M)

was as

calcium.

Although these findings provide evidence against an effect of
calcium on the action of normorphine, they do not directly refute
a possible effect of normorphine on calcium action in the nerve
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terminal.

However, the affinity of normorphine for the opiate

receptor and the efficacy of the resulting drug-receptor complex
are unlikely to be calcium dependent.

5.
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